[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 492
6. Buscombe J, Hirji H, Witney-Smith C: Nuclear medicine in the management of thyroid disease. Expert Rev Anticancer Ther; 2008 Sep;8(9):1425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear medicine in the management of thyroid disease.
  • Thyroid disease management has changed little over the last 60 years and recent work suggests that the older approach remains the most effective.
  • Treatment of benign hyperthyroidism has shown that functional imaging is essentially linked to therapy and uptake of iodine-131 ((131)I) cannot be assumed but should be tested by pre-imaging with radio-isotopes as 10% of patients may not be suitable for (131)I therapy and 1% may have a co-existent cancer.
  • Differentiated thyroid cancer remains unique in that it is almost alone among common solid tumors in that it is routinely cured even if cannot all be removed by surgery.
  • However, in some differentiated thyroid cancers there is no accumulation of (131)I and we know this is due to the loss, or downregulation of the sodium iodide symporter gene.
  • Advances in imaging especially using (18)F-fluorodeoxy-glucose PET has enabled patients with thyroid cancer to be more accurately imaged, resulting in a greater chance of cure through surgery and external-beam radiotherapy, especially if uptake of (131)I is poor.
  • Another approach has been the idea of using radiolabeled somatostatin analogs, which are able to demonstrate uptake in the tumor and, more recently, beta-emitting isotopes have been used for therapy when other options have failed.
  • Therefore, whilst the treatment of differentiated thyroid cancer is, to some degree, 60 years old, new methods have been proposed and are now being tested in this disease.
  • [MeSH-major] Hyperthyroidism. Iodine Radioisotopes. Thyroid Neoplasms

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18759694.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals
  • [Number-of-references] 33
  •  go-up   go-down


7. van de Luijtgaarden AC, Veth RP, Slootweg PJ, Wijers-Koster PM, Schultze Kool LJ, Bovee JV, van der Graaf WT: Metastatic potential of an aneurysmal bone cyst. Virchows Arch; 2009 Nov;455(5):455-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aneurysmal bone cysts (ABCs) are benign bone tumors consisting of blood-filled cavities lined by connective tissue septa.
  • Diagnosis was confirmed by the presence of a break in the USP6 gene, which is pathognomonic for ABC, in a pulmonary metastasis of our patient.
  • Sarcomatous transformation as an explanation for this behavior was ruled out by demonstrating diploid DNA content in both the pulmonary lesion and the primary tumor.
  • [MeSH-major] Bone Cysts, Aneurysmal / pathology. Bone Neoplasms / pathology. Neoplasms, Second Primary / pathology. Osteosarcoma / pathology. Proto-Oncogene Proteins / genetics. Ubiquitin Thiolesterase / genetics
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Bevacizumab. Carcinoma / complications. Cell Transformation, Neoplastic / pathology. Diabetes Mellitus, Type 2 / complications. Embolization, Therapeutic. Female. Humans. Hyperplasia. In Situ Hybridization, Fluorescence. Kidney Neoplasms / secondary. Lung Neoplasms / secondary. Middle Aged. Thyroid Gland / pathology. Uterine Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):233-4 [10825009.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):311-5 [16755186.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):e1; author reply e2 [16382110.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3419-26 [15735689.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):265-6 [10502326.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):583-602 [19396867.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Oct 15;178(2):155-9 [17954273.001]
  • [Cites] Pediatr Dev Pathol. 2007 Jan-Feb;10(1):46-9 [17378626.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43 [16808643.001]
  • [Cites] Pediatr Dev Pathol. 2001 Jul-Aug;4(4):418-9 [11441369.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):177-80 [11566352.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):636-9 [11764383.001]
  • [Cites] Anal Cell Pathol. 2001;23(2):89-95 [11904464.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • [Cites] J Formos Med Assoc. 2003 Sep;102(9):631-6 [14625608.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1920-3 [15026324.001]
  • [Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1773-80 [15509545.001]
  • [Cites] Pediatr Radiol. 1986;16(2):140-3 [3456553.001]
  • [Cites] Skeletal Radiol. 1987;16(3):196-200 [3473690.001]
  • [Cites] Cancer. 1988 Jun 15;61(12):2532-40 [3163257.001]
  • [Cites] Ital J Orthop Traumatol. 1987 Dec;13(4):425-36 [3503870.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jan;58(1):2-13 [1728946.001]
  • [Cites] Cancer. 1992 Jun 15;69(12):2921-31 [1591685.001]
  • [Cites] Surg Today. 1994;24(5):476-80 [8054822.001]
  • [Cites] Cytometry. 1995 Mar 1;19(3):256-62 [7736870.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 1;84(1):27-31 [7497439.001]
  • [Cites] Pathologe. 1996 Jan;17(1):44-9 [8685095.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • (PMID = 19838726.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 2S9ZZM9Q9V / Bevacizumab; EC 3.1.2.15 / USP6 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  •  go-up   go-down


8. Smith JA, Fan CY, Zou C, Bodenner D, Kokoska MS: Methylation status of genes in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg; 2007 Oct;133(10):1006-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation status of genes in papillary thyroid carcinoma.
  • OBJECTIVES: To determine the methylation status of gene promoter regions using methylation-specific polymerase chain reaction in genes encoding for thyrotropin receptor (TSHR), E-cadherin (ECAD), sodium iodide symporter protein (NIS-L), ataxia telangiectasia mutated (ATM), and death-associated protein kinase (DAPK) proteins and if methylation status correlates with patient variables, tumor factors, or outcome measures among patients with papillary thyroid carcinoma.
  • DESIGN: Database query and retrospective medical chart review for patients with well-differentiated thyroid cancer and nonmalignant thyroid conditions treated at our institutions (1996-2004).
  • Methylation status was then compared with patient variables, tumor factors, and outcome measures for patients with thyroid carcinoma and controls.
  • PATIENTS: The study population comprised 32 patients with papillary thyroid carcinoma and 27 controls.
  • RESULTS: In our patients, all 5 genes were methylated more frequently in papillary thyroid carcinoma than in controls.
  • NIS-L methylation in cancer cells was not associated with methylation in adjacent benign tissue, unlike the other 4 genes.
  • Neither age nor sex affected methylation status, and methylation status did not correlate with extent of the primary tumor or presence of nodal metastasis at diagnosis.
  • CONCLUSIONS: Promoter methylation may be a marker for malignancy in thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary / genetics. DNA, Neoplasm / genetics. Receptors, Thyrotropin / metabolism. Symporters / metabolism. Thyroid Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Humans. Iodine. Male. Methylation. Middle Aged. Polymerase Chain Reaction. Prognosis. Promoter Regions, Genetic / physiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938324.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Receptors, Thyrotropin; 0 / Symporters; 0 / sodium-iodide symporter; 9679TC07X4 / Iodine
  •  go-up   go-down


9. Zagrodzki P, Nicol F, Arthur JR, Słowiaczek M, Walas S, Mrowiec H, Wietecha-Posłuszny R: Selenoenzymes, laboratory parameters, and trace elements in different types of thyroid tumor. Biol Trace Elem Res; 2010 Apr;134(1):25-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selenoenzymes, laboratory parameters, and trace elements in different types of thyroid tumor.
  • This study was performed to investigate selenoenzyme activities and trace element concentrations in thyroid tissues, with reference to other parameters routinely used to characterize thyroid function.
  • This was to reveal relevant parameters as possible additional markers of tumor grade, clinical course, and prognosis of thyroid disorders.
  • The tissue samples were obtained during surgical treatment (total or near total thyroidectomy) of 122 patients with different types of thyroid tumor.
  • In the majority of cases, thyroid benign or malignant tumors were not accompanied by significant derangement of the gland selenoenzymes and of either intrathyroidal or plasma concentration of selenium.
  • Nevertheless, types I and II iodothyronine deiodinases were the most promising (among selenoenzymes) targets for diagnoses and possibly therapy of thyroid tumors.
  • Higher activities of both enzymes in cases with Graves' disease, as compared with other thyroid lesions, suggest their involvement in the pathogenesis of this condition.
  • Patients with struna nodosa had higher levels of thyroid Zn, Cu, and Pb as compared with papillary carcinoma subjects and also a higher level of Cu than follicular carcinoma cases.
  • The above diagnostics may play a similar role to some of the general thyroid function indices, TSH, anti-TG, anti-TPO, and calcitonin, which can partially distinguish between various thyroid tumors.
  • Multivariate statistical methods should be employed to tackle a broad array of thyroid tumor diagnostic data in a short time.
  • [MeSH-major] Selenium / metabolism. Selenoproteins / metabolism. Thyroid Gland. Thyroid Neoplasms / chemistry. Trace Elements / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Biopsy, Fine-Needle. Female. Humans. Iodide Peroxidase / metabolism. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597722.001).
  • [ISSN] 1559-0720
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Selenoproteins; 0 / Trace Elements; EC 1.11.1.8 / Iodide Peroxidase; H6241UJ22B / Selenium
  •  go-up   go-down


10. Fan SQ, Liang QC, Jiang Y: Thyroid teratoma in an 11-month-old infant. Int J Surg; 2008 Dec;6(6):462-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid teratoma in an 11-month-old infant.
  • We report a case of congenital benign thyroid teratoma in an 11-month-old male infant who was found to have right thyroid gland mass since birth.
  • The tumor was 25 x 20 x 15 mm with whole thin capsule and could be easily dissected from the surrounding normal thyroid tissue at surgery.
  • Histologically, tumor had mature derivatives of the three primordial germ layers with a variety of benign and well-differentiated elements.
  • It was the most conspicuous feature that the tumor was composed mainly of the neurological tissue resembling brain tissue with glial cells and ependymal epithelium components.
  • In summary, benign teratoma of thyroid gland in an 11-month-old infant was morphologically and immunophenotypically identified.
  • [MeSH-major] Teratoma / pathology. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19059145.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Ding Z, Ji J, Chen G, Fang H, Yan S, Shen L, Wei J, Yang K, Lu J, Bai Y: Analysis of mitochondrial DNA mutations in D-loop region in thyroid lesions. Biochim Biophys Acta; 2010 Mar;1800(3):271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of mitochondrial DNA mutations in D-loop region in thyroid lesions.
  • METHODS: We analyzed the mutations at the mitochondrial DNA (mtDNA) in patients with different thyroid lesions.
  • In particular, in order to investigate if the accumulation of mtDNA mutations play a role in tumor progression, we studied the highly variable main control region of mtDNA, the displacement-loop (D-loop) in patients with non-tumor nodular goiters, with benign thyroid adenomas, and with malignant thyroid carcinomas.
  • Total thyroid tumor or goiter samples were obtained from 101 patients, matched with nearby normal tissue and blood from the same subject.
  • RESULTS: Noticeably, mitochondrial microsatellite instability (mtMSI) was detected in 2 of 19 nodular goiters (10.53%), and 8 of 77 (10.39%) malignant thyroid carcinomas.
  • In addition, 6 patients, including 5 (6.49%) with malignant thyroid carcinomas and 1 (5.26%) with nodular goiter, were found to harbor point mutations.
  • GENERAL SIGNIFICANCE: Our results indicate that mtDNA alterations in the D-loop region could happen before tumorigenesis in thyroid, and they might also accumulate during tumorigenesis.
  • [MeSH-major] DNA, Mitochondrial / genetics. Goiter / genetics. Microsatellite Instability. Mutation. Thyroid Diseases / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19463899.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Mitochondrial
  •  go-up   go-down


12. Moon WJ, Jung SL, Lee JH, Na DG, Baek JH, Lee YH, Kim J, Kim HS, Byun JS, Lee DH, Thyroid Study Group, Korean Society of Neuro- and Head and Neck Radiology: Benign and malignant thyroid nodules: US differentiation--multicenter retrospective study. Radiology; 2008 Jun;247(3):762-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and malignant thyroid nodules: US differentiation--multicenter retrospective study.
  • PURPOSE: To retrospectively evaluate the diagnostic accuracy of ultrasonographic (US) criteria for the depiction of benign and malignant thyroid nodules by using tissue diagnosis as the reference standard.
  • From January 2003 through June 2003, 8024 consecutive patients had undergone thyroid US at nine affiliated hospitals.
  • A total of 831 patients (716 women, 115 men; mean age, 49.5 years +/- 13.8 [standard deviation]) with 849 nodules (360 malignant, 489 benign) that were diagnosed at surgery or biopsy were included in this study.
  • The US findings for benign nodules were isoechogenicity (sensitivity, 56.6%; specificity, 88.1%; P < .001) and a spongiform appearance (sensitivity, 10.4%; specificity, 99.7%; P < .001).
  • For thyroid nodules with a diameter of 1 cm or less, the sensitivity of microcalcifications was lower than that in larger nodules (36.6% vs 51.4%, P < .05).
  • CONCLUSION: Shape, margin, echogenicity, and presence of calcification are helpful criteria for the discrimination of malignant from benign nodules; the diagnostic accuracy of US criteria is dependent on tumor size.
  • [MeSH-major] Thyroid Nodule / ultrasonography
  • [MeSH-minor] Chi-Square Distribution. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Regression Analysis. Retrospective Studies. Sensitivity and Specificity

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • [CommentIn] Radiology. 2008 Jun;247(3):602-4 [18487528.001]
  • (PMID = 18403624.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


13. Hedayati M, Kołomecki K, Pasieka Z, Korzeniowska M, Kuzdak K: [Assessment of VEGF and VEGF receptor concentrations in patients with benign and malignant thyroid tumors]. Endokrynol Pol; 2005 May-Jun;56(3):252-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of VEGF and VEGF receptor concentrations in patients with benign and malignant thyroid tumors].
  • Assessment of the tissue expression and measurement of the concentrations of angiogenic and antiangiogenic factors, contributing to this process, in body fluids, can be used not only for an early diagnosis of tumors and their staging but also as an important parameter of treatment efficiency evaluation.
  • The aim of this study is to evaluate the concentrations of crucial angiogenic cytokine VEGF and its soluble receptors in peripheral blood of patients with benign and malignant thyroid tumors.
  • The study comprised 35 patients with thyroid cancer and 10 patients with follicular neoplasm, both diagnosed by means of ultrasound-guided fine-needle aspiration biopsy.
  • Analysing obtained results, we demonstrated high VEGF concentrations and low soluble VEGF receptor concentrations in patients with benign and malignant thyroid tumors.
  • This fact confirms a vital role of VEGF in angiogenesis of thyroid tumors and a hypothetical antiangiogenic activity of its soluble receptors.
  • Disequilibrium of the above-mentioned angiogenic factor concentrations is probably essential for the growth and progression of benign and malignant thyroid tumors.
  • [MeSH-major] Biomarkers, Tumor / blood. Receptors, Vascular Endothelial Growth Factor / blood. Thyroid Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / diagnosis. Adult. Aged. Biopsy. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16350718.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


1
Advertisement
4. Pauzar B, Staklenac B, Loncar B: Fine needle aspiration biopsy of follicular thyroid tumors. Coll Antropol; 2010 Mar;34(1):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration biopsy of follicular thyroid tumors.
  • US-guided fine needle aspiration cytology is currently the best diagnostic tool for thyroid nodules.
  • The aim of this research was to make a detailed and objective determination of the morphological characteristics of cells in cytological smears in an attempt to distinguish benign from malignant follicular tumors.
  • The statistical analysis of cytological parameters has indicated that none of the cytological parameters alone is discriminating enough between non-tumor and tumor changes, or benign and malignant follicular thyroid nodules.
  • The analysis of age, sex, nodule size and ultrasound findings has not shown the correlation between any of these parameters with the malignant or benign follicular tumors.
  • The cytological analysis of the smears for patients with follicular tumors, in combination with clinical data and other diagnostic methods, contributes to more precise diagnostics, but is not sufficient for the differentiation between benign and malignant follicular tumors.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Biopsy, Fine-Needle / standards. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Nucleus / pathology. Cytoplasm / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Male. Middle Aged. Neoplasms / pathology. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432738.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Croatia
  •  go-up   go-down


15. Kebebew E, Peng M, Reiff E, McMillan A: Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer; 2006 Jun 15;106(12):2592-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms.
  • BACKGROUND: Approximately 30% of fine-needle aspiration (FNA) biopsies of thyroid nodules are indeterminate, nondiagnostic, or suspicious.
  • The purpose of the current study was to determine the accuracy of novel candidate diagnostic markers to distinguish benign from malignant thyroid neoplasms, and to predict the extent of disease.
  • METHODS: A real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) assay of 6 novel candidate diagnostic and extent of disease marker genes (extracellular matrix protein 1 [ECM1]; transmembrane protease, serine 4 [TMPRSS4]; angiopoietin 2 [ANGPT2]; TIMP metallopeptidase inhibitor 1 [TIMP1]; ephrin-B2 [EFNB2], and epidermal growth factor receptor [EGFR]) was used in 126 thyroid tissues.
  • RESULTS: The levels of ECM1, TMPRSS4, ANGPT2, and TIMP1 mRNA expression were found to be independent diagnostic markers of malignant thyroid neoplasms.
  • In 31 thyroid nodule FNA biopsy samples, the scoring model had a sensitivity of 91.0%, a specificity of 95.0%, a positive predictive value of 92.9%, and a negative predictive value of 92.3%.
  • In 11 malignant thyroid nodule FNA samples, the extent of disease scoring model correctly identified 3 of 4 high-risk differentiated thyroid cancers and 7 of 7 low-risk differentiated thyroid cancers.
  • CONCLUSIONS: This novel multigene assay is an excellent diagnostic and extent of disease marker for differentiated thyroid cancer and would be a helpful adjunct to FNA biopsy of thyroid nodules.
  • [MeSH-major] Biomarkers, Tumor / genetics. Genes, Neoplasm / genetics. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics
  • [MeSH-minor] Angiopoietin-2 / analysis. Angiopoietin-2 / genetics. Biopsy, Fine-Needle. Data Interpretation, Statistical. Diagnosis, Differential. Ephrin-B2 / analysis. Ephrin-B2 / genetics. Extracellular Matrix Proteins / analysis. Extracellular Matrix Proteins / genetics. Humans. Predictive Value of Tests. Prognosis. RNA, Messenger / analysis. RNA, Messenger / genetics. ROC Curve. Receptor, Epidermal Growth Factor / analysis. Receptor, Epidermal Growth Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Serine Endopeptidases / analysis. Serine Endopeptidases / genetics. Thyroid Diseases / diagnosis. Thyroid Diseases / genetics. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-1 / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16688775.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiopoietin-2; 0 / Biomarkers, Tumor; 0 / ECM1 protein, human; 0 / Ephrin-B2; 0 / Extracellular Matrix Proteins; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / transmembrane serine protease 2, human
  •  go-up   go-down


16. Kobayashi K, Fukata S, Miyauchi A: Diagnosis of follicular carcinoma of the thyroid: role of sonography in preoperative diagnosis of follicular nodules. J Med Ultrason (2001); 2005 Dec;32(4):153-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of follicular carcinoma of the thyroid: role of sonography in preoperative diagnosis of follicular nodules.
  • The purpose of this study was to evaluate sonographic examination, as well as other clinical tests, for clarifying the parameters for predicting follicular carcinoma in follicular nodules of the thyroid.
  • Nine hundred and ten consecutive patients with follicular nodules were pathologically classified as having follicular carcinoma (109 patients) or benign tumor (811 patients).
  • Benign tumors included follicular adenoma (237 patients) and adenomatous thyroid nodules (574 patients).
  • A case-control study was performed for follicular carcinomas and benign tumors.
  • "Thyroglobulin 1000 ng/ml≦", "cytology class 3≦", and a "solid pattern", "low-echoic level of internal echo", and "jagged borders" of follicular carcinomas were found to be significantly higher than those of benign tumors.
  • We concluded that thyroglobulin 1000 ng/ml≦ and cytology class 3≦ in clinical features, and a solid pattern, low-echoic level, and jagged borders on sonography, indicated an increased risk of follicular carcinoma of the thyroid in follicular nodules.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thyroid. 1998 May;8(5):377-83 [9623727.001]
  • [Cites] Thyroid. 2003 May;13(5):479-84 [12855015.001]
  • [Cites] Thyroid. 2000 Aug;10(8):709-12 [11014317.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):495-8; discussion 499 [7725734.001]
  • [Cites] J Clin Ultrasound. 1995 Mar-Apr;23 (3):179-84 [7730464.001]
  • [Cites] Thyroid. 1998 Nov;8(11):989-95 [9848711.001]
  • [Cites] Mayo Clin Proc. 1997 Oct;72(10):913-6 [9379692.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3668-73 [12915653.001]
  • [Cites] Acta Cytol. 1997 May-Jun;41(3):687-91 [9167684.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):282-9 [8420446.001]
  • [Cites] Radiology. 1985 Apr;155(1):187-91 [3883413.001]
  • [Cites] JAMA. 1983 Jun 3;249(21):2941-4 [6341650.001]
  • [Cites] Eur J Surg Oncol. 1998 Dec;24(6):553-7 [9870733.001]
  • [Cites] Arch Intern Med. 1990 Jul;150(7):1422-7 [2196027.001]
  • (PMID = 27277482.001).
  • [ISSN] 1346-4523
  • [Journal-full-title] Journal of medical ultrasonics (2001)
  • [ISO-abbreviation] J Med Ultrason (2001)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; cytology / follicular carcinoma / sonography / thyroglobulin / thyroid
  •  go-up   go-down


17. Gonçalves AP, Jorge CS, Resende JP, Villela JR, Soares MM, Ramos AV: [Benign hepatic cyst mimicking thyroid carcinoma metastasis]. Arq Bras Endocrinol Metabol; 2009 Aug;53(6):777-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign hepatic cyst mimicking thyroid carcinoma metastasis].
  • [Transliterated title] Cisto hepático benigno simulando metástase de carcinoma diferenciado de tireoide.
  • INTRODUCTION: The follow-up of differentiated thyroid carcinoma (DTC) for detecting persistent or recurrent disease is based on iodine whole body scan (WBS), the evaluation of the tumor marker thyroglobulin (Tg), the anti-thyroglobulin antibody (anti-Tg) and neck ultrasonography (US).
  • Well known false-positive causes of WBS include inflammatory processes, some non-thyroid tumors, kidney or even sebaceous cysts .
  • RESULTS: We enphasize the importance of recognizing benign liver cysts mimicking DTC metastasis.
  • [MeSH-major] Carcinoma, Papillary / radionuclide imaging. Cysts / radionuclide imaging. Iodine Radioisotopes. Liver Diseases / radionuclide imaging. Thyroid Neoplasms
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Thyroglobulin / therapeutic use. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893923.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


18. Chiappetta G, Ammirante M, Basile A, Rosati A, Festa M, Monaco M, Vuttariello E, Pasquinelli R, Arra C, Zerilli M, Todaro M, Stassi G, Pezzullo L, Gentilella A, Tosco A, Pascale M, Marzullo L, Belisario MA, Turco MC, Leone A: The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Clin Endocrinol Metab; 2007 Mar;92(3):1159-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.
  • The expression of BAG3 in other tumor types has not been extensively investigated so far.
  • OBJECTIVE: The objective of this study was to analyze BAG3 expression in thyroid neoplastic cells and investigate its influence in cell apoptotic response to TNF-related apoptosis-inducing ligand (TRAIL).
  • DESIGN, SETTING, AND PATIENTS: We investigated BAG3 expression in human thyroid carcinoma cell lines, including NPA, and the effect of BAG3-specific small interfering RNA on TRAIL-induced apoptosis in NPA cells.
  • Subsequently, we analyzed BAG3 expression in 30 benign lesions and 56 carcinomas from patients of the Naples Tumor Institute Fondazione Senatore Pascale.
  • MAIN OUTCOME MEASURES: The main outcome measures were: analysis of BAG3 protein in NPA cells by Western blot and immunocytochemistry; analysis of apoptosis in TRAIL-stimulated NPA cells by flow cytometry; and evaluation of BAG3 expression in specimens from thyroid lesions by immunohistochemistry.
  • RESULTS: BAG3 was expressed in human thyroid carcinoma cell lines; small interfering RNA-mediated downmodulation of its levels significantly (P < 0.0195) enhanced NPA cell apoptotic response to TRAIL.
  • The protein was not detectable in 19 of 20 specimens of normal thyroid or goiters, whereas 54 of 56 analyzed carcinomas (15 follicular, 28 papillary, and 13 anaplastic) were clearly positive for BAG3 expression.
  • CONCLUSIONS: BAG3 downmodulates the apoptotic response to TRAIL in human neoplastic thyroid cells.
  • The protein is specifically expressed in thyroid carcinomas and not in normal thyroid tissue or goiter.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Adaptor Proteins, Signal Transducing / physiology. Apoptosis / drug effects. Carcinoma / metabolism. TNF-Related Apoptosis-Inducing Ligand / pharmacology. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Apoptosis Regulatory Proteins / metabolism. Cell Line, Tumor. Dose-Response Relationship, Drug. Humans. Immunohistochemistry. RNA, Small Interfering / pharmacology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164298.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Apoptosis Regulatory Proteins; 0 / BAG3 protein, human; 0 / RNA, Small Interfering; 0 / TNF-Related Apoptosis-Inducing Ligand
  •  go-up   go-down


19. Savin S, Cvejic D, Isic T, Petrovic I, Paunovic I, Tatic S, Havelka M: Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors. Endocr Pathol; 2006;17(1):53-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors.
  • Thyroperoxidase (TPO) is a thyroid-specific enzyme expressed by differentiated thyroid cells.
  • Initial immunohistochemical studies claimed that TPO expression, detected by the monoclonal antibody mAb 47, may be a potentially important diagnostic tool in differentiating malignant from benign lesions.
  • To assess these observations we have evaluated the immunohistochemical expression of TPO in thyroid tissue from 215 patients.
  • The studied material included 87 nonmalignant thyroid lesions and 128 thyroid carcinomas.
  • We found that TPO had a sensitivity of 89.9% for cancer and a specificity of 64.4% for nonmalignant lesions, showing that it does not give a sufficient degree of diagnostic certainty that the lesion is benign.
  • In addition, the variability in the degree of TPO expression found within and between follicular carcinomas, and the significant number of benign adenomas having similar immunostaining patterns, assured us that TPO immunostaining is not sufficiently discriminatory in the differential diagnosis of thyroid cancer versus benign lesions.
  • [MeSH-major] Adenoma / enzymology. Carcinoma / enzymology. Iodide Peroxidase / metabolism. Thyroid Neoplasms / enzymology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Immunoenzyme Techniques. Retrospective Studies. Sensitivity and Specificity. Thyroid Diseases / diagnosis. Thyroid Diseases / enzymology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cesk Patol. 2004 Jan;40(1):18-21 [15035056.001]
  • [Cites] Endocr Pathol. 1998 Winter;9(1):333-338 [12114781.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):524-31 [15487449.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):875-80 [11556840.001]
  • [Cites] J Pathol. 1996 May;179(1):89-94 [8691351.001]
  • [Cites] Cancer Detect Prev. 1996;20(4):285-93 [8818388.001]
  • [Cites] Endocr J. 1996 Feb;43(1):53-60 [8732452.001]
  • [Cites] Pathol Res Pract. 1997;193(10):705-12 [9505263.001]
  • [Cites] J Clin Endocrinol Metab. 1978 May;46(5):791-9 [262767.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Feb 14;174(3):1148-53 [1996981.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3793-800 [12454013.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):529-34 [7725740.001]
  • [Cites] Eur J Endocrinol. 1994 Nov;131(5):474-9 [7952158.001]
  • [Cites] J Biol Chem. 1995 Feb 10;270(6):2478-82 [7852309.001]
  • [Cites] Surgery. 1994 Dec;116(6):1031-5 [7985083.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):871-5 [12820316.001]
  • [Cites] Endocr Pathol. 1999 Autumn;10(3):223-228 [12114702.001]
  • [Cites] Acta Pathol Jpn. 1987 Mar;37(3):425-30 [3618217.001]
  • [Cites] Endocrinol Jpn. 1981 Aug;28(4):381-9 [6305643.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1329-34 [8067701.001]
  • [Cites] Am J Surg. 1990 Sep;160(3):271-6 [2393055.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3036-41 [1710535.001]
  • [Cites] Exp Clin Endocrinol. 1992;100(1-2):51-6 [1281780.001]
  • [Cites] Biochemistry. 2001 Feb 27;40(8):2572-9 [11327880.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Aug;53(2):161-9 [10931096.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 28;1689(2):134-41 [15196594.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Nov;45(5):1089-96 [925133.001]
  • [Cites] Surgery. 1999 Dec;126(6):1200-4 [10598208.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Apr;78(4):867-71 [8157713.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17 ):4744-9 [8062273.001]
  • [Cites] Arch Biochem Biophys. 1996 Jun 1;330(1):24-32 [8651700.001]
  • [Cites] Thyroid. 1998 Sep;8(9):745-9 [9777743.001]
  • [Cites] Thyroid. 2000 Feb;10(2):109-15 [10718546.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4977-83 [14557483.001]
  • (PMID = 16760580.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


20. Chia SY, Milas M, Reddy SK, Siperstein A, Skugor M, Brainard J, Gupta MK: Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer. J Clin Endocrinol Metab; 2007 Feb;92(2):468-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer.
  • CONTEXT: Thyroid cancer cells express TSH receptor (TSHR) mRNA, and its measurement in the circulation may be useful in the diagnosis/management of differentiated thyroid cancer (DTC).
  • OBJECTIVE: Our objective was to assess the diagnostic value of circulating TSHR mRNA for preoperative detection of DTC in patients with thyroid nodules.
  • PATIENTS: We measured TSHR mRNA levels by RT-PCR in 258 subjects: 51 healthy subjects and 207 patients (thyroid nodules, n = 180; recurrent thyroid cancer, n = 27) with fine-needle aspirations (FNA) and/or thyroid/neck surgery.
  • RESULTS: Based on cytology/pathology, 88 patients had DTC and 119 had benign thyroid disease.
  • The TSHR mRNA levels in cancer patients were significantly higher than in benign disease (P < 0.0001).
  • Of 131 patients with FNA and surgery, 51 were FNA positive (all cancer), 17 were FNA negative (15 benign, two cancer), and 63 were indeterminate.
  • TSHR mRNA correctly diagnosed DTC in 16 of 24 (67%) and benign disease in 29 of 39 (74%) patients with indeterminate FNA (combined sensitivity = 90%; specificity = 80%).
  • Combining TSHR mRNA and ultrasound features for follicular lesions correctly classified all follicular cancers and could have spared surgery in 31% of these patients with benign disease.
  • CONCLUSIONS: TSHR mRNA measured with FNA enhances the preoperative detection of cancer in patients with thyroid nodules, reducing unnecessary surgeries, and immediate postoperative levels can predict residual/metastatic disease.
  • [MeSH-major] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / pathology. Biomarkers, Tumor / blood. Neoplastic Cells, Circulating. Receptors, Thyrotropin / genetics. Thyroid Neoplasms / blood. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Autoantibodies / blood. Biopsy, Fine-Needle. Female. Humans. Iodine Radioisotopes. Male. Middle Aged. Neoplasm, Residual / blood. Neoplasm, Residual / diagnosis. Predictive Value of Tests. Preoperative Care. RNA, Messenger / blood. Sensitivity and Specificity. Thyroglobulin / immunology. Thyroid Nodule / blood. Thyroid Nodule / pathology. Thyroid Nodule / radionuclide imaging. Thyroid Nodule / surgery. Thyroidectomy. Whole Body Imaging

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118994.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Iodine Radioisotopes; 0 / RNA, Messenger; 0 / Receptors, Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


21. Krzysztof K, Wiktor B, Tadeusz Ł, Waldemar B, Magdalena K, Janusz D: Neuroendocrine tumours--analysis of own material--a nine--year retrospective study. Hepatogastroenterology; 2010 Mar-Apr;57(98):236-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Neuroendocrine tumours are fairly rare neoplasms that require different treatments and have various prognoses.
  • The aim of this study was to present the author's observations of the histological tumor types, occurrence and its surgical treatment.
  • Ultrasonography, scintigraphy, computed tomography or magnetic resonance imaging of abdominal cavity, pelvis, thorax or neck--depend on the tumor localization--were done in every individual.
  • All cases were subjected to surgical procedure with an aim to resect the tumour completely.
  • In the study we have also 11 cases of medullary thyroid carcinomas.
  • In adrenal glands we observed 10 benign and 1 malignant pheochromocytoma (one bilateral female case with Multiple Endocrine Neoplasia type 2A).
  • The clinical manifestations of some neuroendocrine tumours are not specific, so it causes a lot of difficulties in early diagnosis and treatment.
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Neuroendocrine Tumors / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583420.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


22. Hemerly JP, Bastos AU, Cerutti JM: Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol; 2010 Nov;163(5):747-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas.
  • OBJECTIVES: To determine whether IDH1 had somatically acquired mutations in thyroid carcinomas.
  • DESIGN: Exons 4 and 6 of IDH1 were sequenced in a large panel of thyroid tumours (n=138) and compared with the patients normal DNA (n=26).
  • RESULTS: We identified four novel and two previously described non-synonymous variants in thyroid carcinomas, which were absent in benign tumours and paired normal thyroid.
  • Although IDH1 variants occurred at higher frequency in follicular thyroid carcinomas, follicular variant of papillary thyroid carcinoma (PTC) and undifferentiated thyroid carcinomas than the observed variants in classical PTC (15/72 vs 3/37), it was not significant (P=0.1).
  • CONCLUSION: IDH1-acquired genetic alterations are highly prevalent in thyroid carcinomas (16%).
  • Our findings not only extend our understanding of the molecular mechanism underlying pathogenesis of thyroid tumours, but also emphasize the biological differences between tumour types.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20702649.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


23. Federico A, Pallante P, Bianco M, Ferraro A, Esposito F, Monti M, Cozzolino M, Keller S, Fedele M, Leone V, Troncone G, Chiariotti L, Pucci P, Fusco A: Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res; 2009 Sep 1;69(17):7079-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromobox protein homologue 7 (CBX7) is a chromobox family protein encoding a novel polycomb protein, the expression of which shows a progressive reduction, well related with the malignant grade of the thyroid neoplasias.
  • Indeed, CBX7 protein levels decreased in an increasing percentage of cases going from benign adenomas to papillary, follicular, and anaplastic thyroid carcinomas.
  • Consistent with these data, we found a positive statistical correlation between CBX7 and E-cadherin expression in human thyroid carcinomas.
  • [MeSH-minor] Acetylation. Animals. Cell Line, Tumor. Down-Regulation. Enzyme Activation / genetics. Histone Deacetylase 2. Histone Deacetylase Inhibitors. Histones / metabolism. Humans. Polycomb Repressive Complex 1. Proteomics. Rats. Rats, Inbred F344

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706751.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBX7 protein, human; 0 / Cadherins; 0 / Histone Deacetylase Inhibitors; 0 / Histones; 0 / Repressor Proteins; EC 3.5.1.98 / Hdac2 protein, rat; EC 3.5.1.98 / Histone Deacetylase 2; EC 3.5.1.98 / Histone Deacetylases; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


24. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A: ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg; 2005 Sep;242(3):353-61; discussion 361-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy.
  • OBJECTIVE: The objective of this study was to determine whether genes that regulate cellular invasion and metastasis are differentially expressed and could serve as diagnostic markers of malignant thyroid nodules.
  • SUMMARY AND BACKGROUND DATA: Patients whose thyroid nodules have indeterminate or suspicious cytologic features on fine needle aspiration (FNA) biopsy require thyroidectomy because of a 20% to 30% risk of thyroid cancer.
  • METHODS: Differentially expressed genes (2-fold higher or lower) in malignant versus benign thyroid neoplasms were identified by extracellular matrix and adhesion molecule cDNA array analysis and confirmed by real-time quantitative polymerase chain reaction (PCR).
  • RESULTS: By cDNA array analysis, ADAMTS8, ECM1, MMP8, PLAU, SELP, and TMPRSS4 were upregulated, and by quantitative PCR, ECM1, SELP, and TMPRSS4 mRNA expression was higher in malignant (n = 57) than in benign (n = 38) thyroid neoplasms (P< 0.002).
  • ECM1 and TMPRSS4 mRNA expression levels were independent predictors of a malignant thyroid neoplasm (P < 0.003).
  • The level of ECM1 mRNA expression was higher in TNM stage I differentiated thyroid cancers than in stage II and III tumors (P < or = 0.031).
  • CONCLUSIONS: ECM1 and TMPRSS4 are excellent diagnostic markers of malignant thyroid nodules and may be used to improve the diagnostic accuracy of FNA biopsy.
  • ECM1 is also a marker of the extent of disease in differentiated thyroid cancers.
  • [MeSH-major] Biomarkers, Tumor / genetics. Extracellular Matrix Proteins / genetics. Membrane Proteins / genetics. Serine Endopeptidases / genetics. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics
  • [MeSH-minor] Biopsy, Fine-Needle. Gene Expression. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):951-5 [10084577.001]
  • [Cites] J Pathol. 1998 Nov;186(3):287-91 [10211118.001]
  • [Cites] Histopathology. 1999 May;34(5):453-61 [10231421.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):678-85 [10366150.001]
  • [Cites] BMC Bioinformatics. 2004 Oct 25;5:159 [15504239.001]
  • [Cites] World J Surg. 2004 Nov;28(11):1099-102 [15490050.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2602-6 [10825129.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Cancer. 2000 Dec 25;90(6):335-41 [11156516.001]
  • [Cites] Bone. 2001 Jan;28(1):14-20 [11165938.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):41-7 [11163149.001]
  • [Cites] FASEB J. 2001 Apr;15(6):988-94 [11292659.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2187-90 [11344225.001]
  • [Cites] Thyroid. 2001 Aug;11(8):783-7 [11525273.001]
  • [Cites] Trends Biotechnol. 2001 Nov;19(11):463-8 [11602311.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5152-8 [11701669.001]
  • [Cites] Endocr Pathol. 2001 Fall;12(3):275-9 [11740048.001]
  • [Cites] Diagn Cytopathol. 2002 Jan;26(1):41-4 [11782086.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 [11929952.001]
  • [Cites] Int J Biol Markers. 2002 Jan-Mar;17(1):56-62 [11936588.001]
  • [Cites] Histopathology. 2002 Feb;40(2):133-42 [11952857.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] Thyroid. 2004 Apr;14(4):287-93 [15142362.001]
  • [Cites] Surg Clin North Am. 2004 Jun;84(3):907-19 [15145242.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3780-9 [15172984.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):3-27 [15221985.001]
  • [Cites] Endocrinol Jpn. 1990 Apr;37(2):247-54 [1699752.001]
  • [Cites] Diagn Cytopathol. 1992;8(1):23-7 [1551363.001]
  • [Cites] Blood Coagul Fibrinolysis. 2001 Jan;12(1):43-50 [11229826.001]
  • [Cites] J Immunol Methods. 2001 Apr1;250(1-2):3-13 [11251218.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23 [15240595.001]
  • [Cites] Endocr J. 2004 Jun;51(3):361-6 [15256783.001]
  • [Cites] Curr Med Chem. 2004 Aug;11(16):2153-60 [15279555.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):732-8 [15238980.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):183-8 [15252732.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3531-9 [15337802.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5762-8 [15355904.001]
  • [Cites] Eur J Endocrinol. 2004 Sep;151(3):367-74 [15362967.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5175-80 [15472223.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):524-31 [15487449.001]
  • [Cites] Histopathology. 1987 Jul;11(7):723-31 [3623436.001]
  • [Cites] Cancer Res. 1988 Oct 1;48(19):5503-9 [3046740.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):282-9 [8420446.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • [Cites] Mayo Clin Proc. 1993 Apr;68(4):343-8 [8455392.001]
  • [Cites] Clin Lab Med. 1993 Sep;13(3):699-709 [8222583.001]
  • [Cites] Mod Pathol. 1994 Apr;7(3):295-300 [7520169.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4744-9 [8062273.001]
  • [Cites] Mod Pathol. 1994 Jun;7(5):529-32 [7937716.001]
  • [Cites] Surgery. 1994 Dec;116(6):1054-60 [7985087.001]
  • [Cites] Cancer Lett. 1996 May 15;103(1):57-63 [8616809.001]
  • [Cites] Acta Cytol. 1996 May-Jun;40(3):408-13 [8669170.001]
  • [Cites] Dermatology. 1996;192(2):89-93 [8829517.001]
  • [Cites] Diagn Cytopathol. 1996 Jun;14(4):287-91 [8725126.001]
  • [Cites] Histochem Cell Biol. 1996 Dec;106(6):551-62 [8985743.001]
  • [Cites] Laryngoscope. 1997 Jan;107(1):95-100 [9001272.001]
  • [Cites] Pathol Int. 1997 Oct;47(10):673-9 [9361100.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):539-44 [11956624.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):710-3 [12033961.001]
  • [Cites] Exp Hematol. 2002 Jun;30(6):503-12 [12063017.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):3-16 [12114746.001]
  • [Cites] Biotechniques. 2002 Jul;33(1):108, 110, 112-3, passim [12139235.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52 [12161538.001]
  • [Cites] Am J Clin Pathol. 2002 Aug;118(2):165-6 [12162672.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1016-23 [12170088.001]
  • [Cites] Histopathology. 2002 Sep;41(3):236-43 [12207785.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1294-301 [12481010.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):354-7 [12519876.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;975:24-32 [12538151.001]
  • [Cites] Cancer Lett. 2003 Mar 10;191(2):223-7 [12618337.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):271-88 [12665646.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):301-11 [12665648.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):17491-9 [12604605.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1792-800 [12738736.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):237-58 [12784999.001]
  • [Cites] Biostatistics. 2003 Jul;4(3):465-77 [12925512.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5 [12970322.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):57-67 [14550953.001]
  • [Cites] Pol J Pathol. 2003;54(2):111-5 [14575419.001]
  • [Cites] BMC Bioinformatics. 2002 Aug 23;3:22 [12194703.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):449-53 [14585093.001]
  • [Cites] Curr Mol Med. 2003 Nov;3(7):659-71 [14601640.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):517-9 [14870775.001]
  • [Cites] Physiol Genomics. 2004 Feb 13;16(3):361-70 [14645736.001]
  • [Cites] FASEB J. 2004 Mar;18(3):560-1 [14715705.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):309-12 [14999471.001]
  • [Cites] Matrix Biol. 1997 Nov;16(5):289-92 [9501329.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):169-74 [9504687.001]
  • [Cites] Thyroid. 1998 May;8(5):377-83 [9623727.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3015-20 [9679965.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9325-30 [9689079.001]
  • [Cites] Thyroid. 1998 Nov;8(11):981-7 [9848710.001]
  • [Cites] Int J Cancer. 1999 Jan 5;80(1):32-8 [9935226.001]
  • (PMID = 16135921.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / ECM1 protein, human; 0 / Extracellular Matrix Proteins; 0 / Membrane Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / transmembrane serine protease 2, human
  • [Other-IDs] NLM/ PMC1357743
  •  go-up   go-down


25. Guida M, Mandato VD, Di Spiezio Sardo A, Di Carlo C, Giordano E, Nappi C: Coexistence of Graves' disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels. J Endocrinol Invest; 2005 Oct;28(9):827-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of Graves' disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels.
  • BACKGROUND: Struma ovarii is the most common monodermal ovarian teratoma and consists mainly of thyroid tissue.
  • Only 5% of patients with this tumor have features of hyperthyroidism.
  • CASE: We describe a case of benign struma ovarii, presenting with the clinical features of an ovarian cancer: large complex pelvic mass, large amount of ascites and markedly elevated CA-125 serum levels.
  • [MeSH-major] CA-125 Antigen / blood. Graves Disease / etiology. Graves Disease / therapy. Ovarian Neoplasms / etiology. Ovarian Neoplasms / surgery. Struma Ovarii / etiology. Struma Ovarii / surgery

  • Genetic Alliance. consumer health - Graves' Disease.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. METHIMAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Postgrad Med J. 1990 Feb;66(772):132-3 [2349185.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Feb;70(2):444-52 [1688867.001]
  • [Cites] Gynecol Oncol. 1995 Dec;59(3):405-8 [8522265.001]
  • [Cites] Clin Nucl Med. 1992 Jul;17 (7):577-8 [1638839.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1994 Jun 30;55(3):205-8 [7958166.001]
  • [Cites] Gynecol Oncol. 1989 Feb;32(2):224-7 [2910784.001]
  • [Cites] Eur J Endocrinol. 2004 Apr;150(4):431-7 [15080771.001]
  • [Cites] Gynecol Oncol. 2002 Aug;86(2):231-4 [12144834.001]
  • [Cites] Am J Surg Pathol. 1995 Jan;19(1):21-9 [7802134.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 1996 Aug;36(3):372-3 [8883774.001]
  • [Cites] Cell Immunol. 1995 Apr 1;161(2):262-9 [7697737.001]
  • (PMID = 16370564.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CA-125 Antigen; 554Z48XN5E / Methimazole; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


26. Alessio HM, Schweitzer NB, Snedden AM, Callahan P, Hagerman AE: Revisiting influences on tumor development focusing on laboratory housing. J Am Assoc Lab Anim Sci; 2009 May;48(3):258-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting influences on tumor development focusing on laboratory housing.
  • Tumor profiles and tumor promoting hormone prolactin were compared in female Sprague-Dawley rats (108) that were allocated into 3 groups: those housed without outside activity (SED group), with twice-weekly 1-h sessions of physical activity in large box (PA group), and with regular voluntary running-wheel exercise (EX).
  • Compared with the EX group, SED rats had more and larger tumors throughout most of their lifespan; tumor profiles of PA rats were similar to those of the SED group.
  • At 64 wk, tumors in SED animals included thyroid carcinoma, malignancy, mammary fibroadenoma, cystadenoma, and granuloma, whereas benign mammary gland cysts were most common in EX.
  • In conclusion, increased tumor number, increased tumor size, type of spontaneous tumor, and increased prolactin in rats were associated with standard laboratory housing, which limited physical activity, and were not primarily due to aging.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Endocrinol Metab. 2002 Aug;13(6):245-50 [12128285.001]
  • [Cites] Epidemiol Rev. 2001;23(1):132-7 [11588837.001]
  • [Cites] Med Sci Sports Exerc. 2003 Nov;35(11):1828-33 [14600546.001]
  • [Cites] Med Sci Sports Exerc. 2003 Nov;35(11):1834-40 [14600547.001]
  • [Cites] Cancer Res. 1966 Mar;26(3):400-11 [5948819.001]
  • [Cites] Cancer Res. 1973 Nov;33(11):2768-73 [4748432.001]
  • [Cites] Br J Cancer. 1981 May;43(5):689-95 [7248153.001]
  • [Cites] Neuroendocrinology. 1985 Nov;41(5):437-44 [4058676.001]
  • [Cites] Br J Cancer. 1985 Dec;52(6):885-91 [4074640.001]
  • [Cites] Physiol Behav. 1997 Jul;62(1):105-11 [9226349.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 17;91(6):512-23 [10088621.001]
  • [Cites] Physiol Behav. 2005 Jan 31;84(1):65-72 [15642608.001]
  • [Cites] Med Sci Sports Exerc. 2006 Mar;38(3):405-6 [16540824.001]
  • [Cites] Mol Cell Biochem. 2007 Jan;294(1-2):19-24 [17136443.001]
  • [Cites] Med Sci Sports Exerc. 2000 Oct;32(10):1704-8 [11039641.001]
  • [Cites] Med Sci Sports Exerc. 2000 Nov;32(11):1908-12 [11079521.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):689-96 [12574200.001]
  • (PMID = 19476713.001).
  • [ISSN] 1559-6109
  • [Journal-full-title] Journal of the American Association for Laboratory Animal Science : JAALAS
  • [ISO-abbreviation] J. Am. Assoc. Lab. Anim. Sci.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R15 AG020526; United States / NIA NIH HHS / AG / R15 AG 20526-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-62-4 / Prolactin
  • [Other-IDs] NLM/ PMC2696827
  •  go-up   go-down


27. Guarino E, Tarantini B, Pilli T, Checchi S, Brilli L, Ciuoli C, Di Cairano G, Mazzucato P, Pacini F: Presurgical serum thyroglobulin has no prognostic value in papillary thyroid cancer. Thyroid; 2005 Sep;15(9):1041-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presurgical serum thyroglobulin has no prognostic value in papillary thyroid cancer.
  • We investigated whether serum thyroglobulin determination before surgery for differentiated thyroid carcinoma may have any prognostic value with regard to tumour extension and disease outcome in a retrospective series of 71 patients with papillary thyroid cancer.
  • Presurgical serum thyroglobulin levels were correlated with the size of the primary tumoral nodule (p = 0.006) and of the whole thyroid (p = 0.02).
  • The same correlation was found in a control group of patients with benign thyroid nodules, confirming that presurgical serum thyroglobulin cannot be used for the differential diagnosis of thyroid carcinoma.
  • Presurgical serum thyroglobulin levels did not differ among patients with tumor limited to thyroid gland or extending to cervical lymph nodes or invading outside the thyroid capsule or metastasising to distant size.
  • In addition presurgical serum thyroglobulin levels were not correlated with the disease outcome after a mean follow-up of 9 years: no difference was found among patients in complete remission or with persistent disease or dead from thyroid cancer.
  • [MeSH-major] Carcinoma, Papillary / blood. Carcinoma, Papillary / diagnosis. Thyroglobulin / blood. Thyroid Neoplasms / blood. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16187912.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


28. Kang SW, Lee SC, Lee SH, Lee KY, Jeong JJ, Lee YS, Nam KH, Chang HS, Chung WY, Park CS: Robotic thyroid surgery using a gasless, transaxillary approach and the da Vinci S system: the operative outcomes of 338 consecutive patients. Surgery; 2009 Dec;146(6):1048-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic thyroid surgery using a gasless, transaxillary approach and the da Vinci S system: the operative outcomes of 338 consecutive patients.
  • The authors performed robot-assisted endoscopic thyroid operations in consecutive thyroid tumor patients using the newly introduced da Vinci S surgical system.
  • Herein the authors describe the technique used and its utility for the operative management of thyroid tumors.
  • METHODS: From October 2007 to November 2008, 338 patients underwent robot-assisted endoscopic thyroid operations using a gasless, transaxillary approach.
  • CONCLUSION: Our technique of robotic thyroid surgery using a gasless, transaxillary approach is feasible and safe in selected patients with a benign or malignant thyroid tumor.
  • [MeSH-major] Robotics / methods. Surgery, Computer-Assisted / methods. Thyroid Neoplasms / surgery. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19879615.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Strazisar B, Petric R, Sesek M, Zgajnar J, Hocevar M, Besic N: Predictive factors of carcinoma in 279 patients with Hürthle cell neoplasm of the thyroid gland. J Surg Oncol; 2010 Jun 1;101(7):582-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of carcinoma in 279 patients with Hürthle cell neoplasm of the thyroid gland.
  • BACKGROUND AND OBJECTIVES: Estimation of the risk of malignancy in a Hürthle cell (HC) neoplasm is important for optimum extent of thyroid surgical treatment.
  • The aim of this retrospective study was to find predictive factors of carcinoma in patients with HC neoplasm.
  • METHODS: A total of 279 patients (241 females, 38 males; median age 55 years, range 15-86 years) with HC neoplasm in whom carcinoma was only suspected and who were surgically treated at our Institute in the period 1990-2007, were included in this study.
  • RESULTS: The histopatological diagnoses were carcinoma, benign goiter and adenoma in 71 (25%), 68 (25%) and 140 (50%) patients, respectively.
  • Predictive factors for carcinoma, shown by chi-square test, were: age of patients, tumor diameter, thyroid volume and T(g) concentration.
  • CONCLUSIONS: The independent predictors of malignancy in HC neoplasm were age of patients and pre-operative T(g) concentration.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Risk Factors. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20461764.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Tomoda C, Takamura Y, Ito Y, Miya A, Miyauchi A: Transient vocal cord paralysis after fine-needle aspiration biopsy of thyroid tumor. Thyroid; 2006 Jul;16(7):697-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient vocal cord paralysis after fine-needle aspiration biopsy of thyroid tumor.
  • OBJECTIVE: Complications of thyroid fine-needle aspiration biopsy (FNAB) are exceedingly rare.
  • Here we describe patients diagnosed as having transient vocal cord paralysis after FNAB of benign thyroid tumor.
  • DESIGN: Retrospective review of patients with concurrent diagnosis of vocal cord paralysis after FNAB.
  • These patients had solid and/or cystic lesion in the thyroid.
  • Cytologic findings were benign tumor.
  • CONCLUSION: Although the incidence of vocal cord paralysis in patients with thyroid tumor after FNAB is reported to be 0.036%, the true incidence is unknown because asymptomatic subjects are not screened.
  • [MeSH-major] Biopsy, Fine-Needle / adverse effects. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology. Vocal Cord Paralysis / chemically induced. Vocal Cords / drug effects

  • Genetic Alliance. consumer health - paralysis.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889495.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Porpora MG, Pallante D, Ferro A, Alò PL, Cosmi EV: Asymptomatic struma ovarii: a case report. Clin Exp Obstet Gynecol; 2005;32(3):197-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Struma ovarii is a rare ovarian neoplasm.
  • This tumor is generally benign, although malignant transformation has been reported.
  • The preoperative diagnosis is generally difficult.
  • Thyroid hormones may be produced and in a few cases asymptomatic women may develop definitive clinical hypothyroidism after resection of struma ovarii.
  • The pathologic diagnosis was struma ovarii.
  • The postoperative period was uneventful and her thyroid function remained normal.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Struma Ovarii / diagnosis. Struma Ovarii / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16433164.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


32. Subramanian M, Pilli T, Bhattacharya P, Pacini F, Nikiforov YE, Kanteti PV, Prabhakar BS: Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis. J Clin Endocrinol Metab; 2009 Apr;94(4):1467-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis.
  • AIM: The aim of the study was to investigate the expression and function of the IG20 gene in thyroid cancer cell survival, proliferation, and apoptosis.
  • METHODS: We determined the expression levels of the major isoforms of IG20 by quantitative RT-PCR in normal and thyroid tumor tissues/cell lines.
  • We evaluated the functional consequence of IG20 knockdown in WRO (follicular carcinoma) and FRO (anaplastic carcinoma) thyroid cancer cell lines by measuring spontaneous, TNFalpha-related apoptosis-inducing ligand (TRAIL), and TNFalpha-induced apoptosis.
  • RESULTS: The IG20 gene expression levels were higher in benign and malignant thyroid tumors and in WRO and FRO cells relative to normal tissues.
  • CONCLUSION: IG20 knockdown renders WRO cells more susceptible to spontaneous, TRAIL-, and TNFalpha-induced apoptosis and thus demonstrates the prosurvival function of the IG20 gene in thyroid cancer.
  • These observations, combined with overexpression of IG20 noted in thyroid tumor tissues, may suggest a potential role in thyroid cancer survival and growth and indicate that IG20 may be targeted either alone or in conjunction with TRAIL or TNFalpha treatment in certain thyroid cancers.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4122-9 [10945619.001]
  • [Cites] Nat Med. 1999 Feb;5(2):157-63 [9930862.001]
  • [Cites] J Virol. 2003 Nov;77(22):11964-72 [14581533.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8768-76 [14695193.001]
  • [Cites] Int J Cancer. 2004 Mar10;109(1):24-37 [14735464.001]
  • [Cites] Oncogene. 2004 Feb 5;23(5):1076-87 [14716293.001]
  • [Cites] Oncogene. 2004 Aug 12;23(36):6083-94 [15208670.001]
  • [Cites] Nature. 1993 Aug 26;364(6440):806-9 [7689176.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jul;81(7):2607-12 [8675585.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):255-60 [10209153.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Oncogene. 2006 Oct 12;25(47):6252-61 [16682944.001]
  • [Cites] J Biol Chem. 2007 Apr 20;282(16):11715-21 [17314102.001]
  • [Cites] Expert Rev Mol Diagn. 2008 Jan;8(1):83-95 [18088233.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):347-51 [18223207.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7352-61 [18794122.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):12069-75 [9115275.001]
  • [Cites] J Biol Chem. 2001 Dec 14;276(50):47202-11 [11577081.001]
  • (PMID = 19190106.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107506; United States / NCI NIH HHS / CA / 5R01CA107506
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Death Domain Receptor Signaling Adaptor Proteins; 0 / Guanine Nucleotide Exchange Factors; 0 / MADD protein, human; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2682475
  •  go-up   go-down


33. Gessl A, Raber W, Staudenherz A, Becherer A, Koperek O, Hofmann A: Higher frequency of thyroid tumors in the right lobe. Endocr Pathol; 2010 Sep;21(3):186-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher frequency of thyroid tumors in the right lobe.
  • Recently, using ultrasonography, we observed that the right lobe usually is larger compared with the left thyroid lobe.
  • Since the higher cell number in a larger right lobe may confer a higher tumor risk, we investigated the location of benign and malignant lesions to test the hypothesis of a more frequent occurrence in this lobe.
  • In 1,001 consecutive patients with benign thyroid lesions, tumors more frequently occurred in the right lobe (+21.5%, p = 0.0022).
  • Furthermore, in 1,277 thyroid cancer patients with 1,302 thyroid cancers, the right lobe more often harbored the tumor initially (+22.9%, p = 0.0009).
  • Our data show a larger proportion of both benign and malignant tumors in the right thyroid lobe.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 1988 Apr;28(4):409-14 [3056637.001]
  • [Cites] Clin Transl Oncol. 2006 Sep;8(9):681-7 [17005471.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Jun;66(6):1240-6 [3259584.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Feb;56(2):260-3 [6822636.001]
  • [Cites] Br J Radiol. 1994 Jun;67(798):519-23 [8032803.001]
  • [Cites] Bull World Health Organ. 1997;75(2):95-7 [9185360.001]
  • [Cites] Acta Radiol. 2002 May;43(3):269-74 [12100323.001]
  • [Cites] Front Neuroendocrinol. 1997 Jul;18(3):354-81 [9237081.001]
  • [Cites] Surg Radiol Anat. 2006 Mar;28(1):25-32 [16374571.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 Dec;129(6):505-10 [8109183.001]
  • [Cites] J Ultrasound Med. 2003 Oct;22(10 ):1027-31 [14606557.001]
  • [Cites] Nuklearmedizin. 1981 Apr;20(2):64-71 [7243602.001]
  • [Cites] Hum Mol Genet. 2007 Feb 1;16(3):276-85 [17164259.001]
  • [Cites] Br J Surg. 1969 May;56(5):351-2 [5781045.001]
  • [Cites] Dtsch Med Wochenschr. 1981 Oct 9;106(41):1338-40 [7274082.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Oct;63(4):918-27 [3488999.001]
  • [Cites] Thyroid. 2004 Nov;14 (11):926-32 [15671771.001]
  • [Cites] Clin Endocrinol (Oxf). 1978 Jun;8(6):483-6 [668154.001]
  • [Cites] Eur J Nucl Med. 1997 Dec;24(12 ):1470-8 [9391181.001]
  • [Cites] Dan Med Bull. 1991 Feb;38(1):87-9 [1878025.001]
  • [Cites] Dtsch Med Wochenschr. 1983 Sep 9;108(36):1355-8 [6884221.001]
  • (PMID = 20532675.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Xu MR, Chen Y, Zhou SR, Chi MM, Chen SL, Liu LY: [Expressions of RASSF1A, Galectin-3 and TPO mRNA in papillary thyroid carcinoma and their clinical significance]. Zhonghua Zhong Liu Za Zhi; 2009 May;31(5):356-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of RASSF1A, Galectin-3 and TPO mRNA in papillary thyroid carcinoma and their clinical significance].
  • OBJECTIVE: To investigate the mRNA expressions of RASSF1A, Galectin-3 and TPO in papillary thyroid carcinoma and some other thyroid benign lesions, and evaluate their diagnostic significance.
  • METHODS: Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the mRNA expression of RASSF1A, galectin-3 and TPO in the samples from 73 cases, including 23 cases with papillary thyroid cancer, 16 with nodular goiter, 29 with thyroid adenoma and 5 with Hashimoto's disease.
  • RESULTS: A statistically significant difference in the mRNA expression of RASSF1A, Galectin-3 and TPO was observed between papillary thyroid carcinoma and follicular benign lesions (P<0.05).
  • However, there was no significant difference among various kinds of benign lesions (P>0.05).
  • A negative correlation of the expression of RASSF1A and Galectin-3 mRNA was found between thyroid benign lesions and malignant ones (P = 0.000).
  • While the mRNA expression of RASSF1A and TPO was positively correlated between benign and malignant lesions (P = 0.028).
  • CONCLUSION: Loss of expression of RASSF1A and TPO mRNA but high expression of Galectin-3 mRNA in papillary thyroid carcinoma are common.
  • Therefore, the products of these three genes may be closely related to the development of thyroid papillary carcinoma, and may be used as useful markers in differential diagnosis of papillary thyroid carcinoma from the benign lesions.
  • [MeSH-major] Autoantigens / metabolism. Carcinoma, Papillary / metabolism. Galectin 3 / metabolism. Iodide Peroxidase / metabolism. Iron-Binding Proteins / metabolism. Thyroid Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Goiter, Nodular / genetics. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Hashimoto Disease / genetics. Hashimoto Disease / metabolism. Hashimoto Disease / pathology. Humans. Male. Middle Aged. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799084.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Iron-Binding Proteins; 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; EC 1.11.1.7 / TPO protein, human; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


35. Zhang P, Zuo H, Nakamura Y, Nakamura M, Wakasa T, Kakudo K: Immunohistochemical analysis of thyroid-specific transcription factors in thyroid tumors. Pathol Int; 2006 May;56(5):240-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of thyroid-specific transcription factors in thyroid tumors.
  • Thyroid transcription factor 1 (TTF1), thyroid transcription factor 2 (TTF2) and paired box gene 8 (Pax8) are demonstrated to play a crucial role for the differentiation and organogenesis of thyroid follicular cells.
  • Their roles in thyroid carcinogenesis are not very clear.
  • Because dedifferentiation is a common process in thyroid carcinogenesis, thyroid-specific transcription factors seem also to be involving in thyroid carcinogenesis.
  • The purpose of the present paper was to investigate their expression in a broad spectrum of follicular cell tumors in different degrees of differentiation, from well-differentiated benign follicular adenoma to anaplastic carcinoma.
  • Results of immunohistochemical staining showed that nuclear localization of these transcription factors was gradually decreased corresponding to the progressive dedifferentiation of thyroid tumors.
  • In conclusion, abnormal expression of TTF1, TTF2 and Pax8 was closely related to thyroid tumorigenesis.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. DNA-Binding Proteins / metabolism. Immunohistochemistry / methods. Thyroid Neoplasms / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adenosine Triphosphatases. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Humans. Paired Box Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16669872.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / TTF1 protein, human; 0 / Transcription Factors; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / TTF2 protein, human
  •  go-up   go-down


36. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M: Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer; 2005 Jun;12(2):305-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
  • The distinction of benign from malignant follicular thyroid neoplasms remains a difficult task in diagnostic fine-needle aspiration cytology, and some discrepant results have been reported for the individual immunocytochemical markers of malignancy proposed so far.
  • The aim of this study was to test if the combined use of a panel of markers could improve the diagnostic accuracy in the preoperative cytological evaluation of 'follicular neoplasms' in an attempt to reduce the number of thyroidectomies performed for benign lesions.
  • The immunocytochemical expression of galectin-3, HBME-1, thyroperoxidase, cytokeratin-19 and keratan-sulfate was retrospectively analyzed in 125 consecutive fine-needle aspiration samples (cell blocks) of indeterminate diagnoses of 'follicular thyroid neoplasm', and compared with their corresponding surgical specimens, including 33 follicular carcinomas, 42 papillary carcinomas and 50 follicular adenomas.
  • Our data showed that, as compared with the use of single markers, the sequential combination of two markers represents the most accurate immunohistochemical panel in managing patients with a fine-needle aspiration biopsy diagnosis of 'follicular neoplasms', especially in otherwise controversial categories such as oncocytic tumours.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Biomarkers, Tumor / analysis. Immunohistochemistry. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947105.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Wang JD, Deng XC, Jin XJ, Zhou C, Zhang C, Xie M, Zhou JQ, Qian MF: [Clinical research on 2228 cases of thyroid gland tumors]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2005 Apr;40(4):295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical research on 2228 cases of thyroid gland tumors].
  • OBJECTIVE: To discuss outcome of thyroid tumor patients treated with surgery.
  • These patients of thyroid tumors from 1992-2004 (2072 cases of benign thyroid diseases and 156 cases of thyroid carcinoma) were recruited.
  • (1) Benign thyroid tumors with near-total thyroidectomy including 1761 thyroid adenoma, 207 nodular goiter and 104 Hashimoto thyroiditis, the incidence of recurrent laryngeal nerve paralysis was 0.2%, 55 cases (2.6%) received secondary surgery.
  • All the patients have no hypocalcemia or hemorrhage after operation. (2) Eighty-one cases of papillary carcinoma of the thyroid ( > 1 cm) and 60 cases of microcarcinoma.
  • Unilateral thyroidectomy, contralateral near-total thyroidectomy and ipsilateral modified neck dissection were performed in unilateral papillary carcinoma of thyroid.
  • Among the 9 cases of follicular carcinoma of thyroid, 7 were performed of near-total thyroidectomy without neck dissection, others were the same as papillary carcinoma.
  • Bilateral total thyroidectomy and bilateral modified neck dissection were performed in 2 cases of the medullary thyroid cancer and 1 case of the undifferentiated thyroid cancer.
  • There is no relapse or metastases in 60 cases of papillary thyroid microcarcinoma.
  • The 5-year survival was 100.0%, 1 cases occurred recurrent laryngeal nerve paralysis in thyroid cancer.
  • Eight case relapsed in 156 cases of thyroid carcinoma,3 cases died.
  • CONCLUSION: The correct surgical management for the patients with thyroid tumor should benefit for the prognosis and reduce the complications and the recurrence of the operation.
  • [MeSH-major] Thyroid Neoplasms / surgery. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008266.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


38. Levy R, Grafi-Cohen M, Kraiem Z, Kloog Y: Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas. Mol Cancer Ther; 2010 Aug;9(8):2208-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.
  • Anaplastic thyroid carcinomas are deadly tumors that are highly invasive, particularly into the bones.
  • Although oncogenic Ras can transform thyroid cells into a severely malignant phenotype, thyroid carcinomas do not usually harbor ras gene mutations.
  • Therefore, it is not known whether chronically active Ras contributes to thyroid carcinoma cell proliferation, although galectin-3 (Gal-3), which is strongly expressed in thyroid carcinomas but not in benign tumors or normal glands, is known to act as a K-Ras chaperone that stabilizes and drives K-Ras.GTP nanoclustering and signal robustness.
  • Here, we examined the possibility that thyroid carcinomas expressing high levels of Gal-3 exhibit chronically active K-Ras.
  • Using cell lines representing three types of malignant thyroid tumors--papillary, follicular, and anaplastic--we investigated the possible correlation between Gal-3 expression and active Ras content, and then examined the therapeutic potential of the Ras inhibitor S-trans, trans-farnesylthiosalicylic acid (FTS; Salirasib) for thyroid carcinoma.
  • Thyroid carcinoma cells strongly expressing Gal-3 showed high levels of K-Ras.GTP expression, and K-Ras.GTP transmitted strong signals to extracellular signal-regulated kinase.
  • FTS disrupted interactions between Gal-3 and K.Ras, strongly reduced K-Ras.GTP and phospho-extracellular signal-regulated kinase expression, and enhanced the expression of the cell cycle inhibitor p21 as well as of the thyroid transcription factor 1, which is involved in thyroid cell differentiation.
  • FTS also inhibited anaplastic thyroid carcinoma cell proliferation in vitro and tumor growth in nude mice.
  • We conclude that wild-type K-Ras.GTP in association with Gal-3 contributes to thyroid carcinoma malignancy and that Ras inhibition might be a useful treatment strategy against these deadly tumors.
  • [MeSH-major] Cell Differentiation. Galectin 3 / metabolism. Proto-Oncogene Proteins / metabolism. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology. ras Proteins / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Membrane / drug effects. Cell Membrane / metabolism. Cell Proliferation / drug effects. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Disease Models, Animal. Down-Regulation / drug effects. Enzyme Activation / drug effects. Extracellular Signal-Regulated MAP Kinases / metabolism. Farnesol / analogs & derivatives. Farnesol / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Guanosine Triphosphate / metabolism. Humans. Mice. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Protein Transport / drug effects. Salicylates / pharmacology. Signal Transduction / drug effects. Transcription Factors / genetics. Transcription Factors / metabolism. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FARNESOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • (PMID = 20682656.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Galectin 3; 0 / KRAS protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Salicylates; 0 / Transcription Factors; 0 / farnesylthiosalicylic acid; 0 / thyroid nuclear factor 1; 4602-84-0 / Farnesol; 86-01-1 / Guanosine Triphosphate; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


39. Hunt JL, Yim JH, Carty SE: Fractional allelic loss of tumor suppressor genes identifies malignancy and predicts clinical outcome in follicular thyroid tumors. Thyroid; 2006 Jul;16(7):643-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractional allelic loss of tumor suppressor genes identifies malignancy and predicts clinical outcome in follicular thyroid tumors.
  • Thyroid follicular tumors can be challenging diagnostically and clinically, because the cytologic and histologic features can be subtle and prognosis is also difficult to predict.
  • In this study, we analyzed thyroid follicular tumors with known long-term follow-up for a molecular panel of tumor suppressor genes to determine whether this molecular approach has prognostic significance.
  • Microdissection and DNA extraction were performed from tumor and normal tissue.
  • Polymerase chain reaction (PCR) was performed for 13 short tandem repeats at or near tumor suppressor genes.
  • The mean FAL for benign tumors (14%) was significantly different from that of malignant tumors (56%, p < 0.001).
  • Patients with a follicular tumor who had no evidence of disease recurrence had a mean FAL of 22% and those with disease recurrence or death from disease had a mean of 78% (p < 0.002).
  • Based on these results, a tumor suppressor gene panel for allelic imbalance in follicular-derived tumors (FTT) may correlate with both malignancy and outcome in patients with follicular-derived carcinomas of the thyroid.
  • [MeSH-major] Adenoma / genetics. Adenoma / therapy. Carcinoma / genetics. Carcinoma / therapy. Genes, Tumor Suppressor. Loss of Heterozygosity. Thyroid Neoplasms / genetics. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889487.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 9007-49-2 / DNA
  •  go-up   go-down


40. Gartner W, Mineva I, Daneva T, Baumgartner-Parzer S, Niederle B, Vierhapper H, Weissel M, Wagner L: A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients. Hum Genet; 2005 Jul;117(2-3):143-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients.
  • To investigate endocrine tumor tissue characteristic RET proto-oncogene expression, we performed quantitative RT-PCR, Northern blot and Southern blot analyses of benign and malignant endocrine-derived tissues.
  • In addition, the presence of a 3'-terminally truncated RET proto-oncogene mRNA variant in benign and malignant thyroid neoplasias, as well as in a pheochromocytoma, an ovarian carcinoma and a medullary thyroid carcinoma, is demonstrated.
  • Heterozygous genotypes were found in a significantly higher percentage in samples derived from endocrine tumor patients when compared with those from healthy control subjects.
  • Analysis of DNA derived from varying regions within individual anaplastic thyroid carcinomas revealed an allele 1/allele 2 switch of the RFLP banding pattern, indicating loss of heterozygosity at the RET proto-oncogene locus.
  • A heterozygous genotype for this polymorphism is found in a considerable number of endocrine tumor patients.
  • [MeSH-major] 3' Untranslated Regions / genetics. Endocrine Gland Neoplasms / genetics. Gene Expression Regulation, Neoplastic / genetics. Loss of Heterozygosity / genetics. Oncogene Proteins / genetics. Polymorphism, Restriction Fragment Length. Receptor Protein-Tyrosine Kinases / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1992;61:419-40 [1353951.001]
  • [Cites] Hum Genet. 1996 Mar;97(3):299-303 [8786068.001]
  • [Cites] Dev Biol. 2003 Feb 15;254(2):262-76 [12591246.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):380-3 [8114940.001]
  • [Cites] Mol Cell Neurosci. 1999 May;13(5):313-25 [10356294.001]
  • [Cites] Oncogene. 1995 Nov 16;11(10):2039-45 [7478523.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Pathol. 1994 Mar;172(3):255-60 [8195928.001]
  • [Cites] Nucleic Acids Res. 1996 Jun 15;24(12):2288-94 [8710498.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):785-9 [8657281.001]
  • [Cites] Oncogene. 1995 Apr 6;10(7):1377-83 [7731689.001]
  • [Cites] Oncogene. 1999 Jul 1;18(26):3919-22 [10445857.001]
  • [Cites] J Mol Med (Berl). 2003 Jul;81(7):411-9 [12811413.001]
  • [Cites] Science. 1995 Jan 20;267(5196):381-3 [7824936.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2845-9 [10850426.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):789-93 [8657282.001]
  • [Cites] Oncogene. 2000 Jul 13;19(30):3445-8 [10918602.001]
  • [Cites] Oncogene. 1988 Nov;3(5):571-8 [3078962.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):430-5 [11912494.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):377-8 [8114938.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2979-85 [8187085.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Jun 30;153(3):1290-5 [3390185.001]
  • [Cites] Hum Genet. 1995 Jul;96(1):27-32 [7607650.001]
  • [Cites] Nucleic Acids Res. 1990 Dec 25;18(24):7472 [1979682.001]
  • [Cites] Oncogene. 1990 Jan;5(1):97-102 [2181380.001]
  • [Cites] Biochimie. 1999 Apr;81(4):397-402 [10401675.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1369-73 [10022819.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2575-82 [8361767.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):375-6 [7906866.001]
  • [Cites] Cell. 1990 Feb 23;60(4):557-63 [2406025.001]
  • [Cites] J Cell Physiol. 2003 May;195(2):168-86 [12652644.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):525-30 [9467569.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):380-93 [10458257.001]
  • [Cites] Cell. 1985 Jun;41(2):349-59 [2580642.001]
  • [Cites] Int J Oncol. 2003 Oct;23(4):1025-32 [12963982.001]
  • [Cites] Oncogene. 1990 Oct;5(10):1595-8 [1701232.001]
  • [Cites] Adv Anat Pathol. 2001 Nov;8(6):345-54 [11707626.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5590-7 [11114739.001]
  • (PMID = 15841388.001).
  • [ISSN] 0340-6717
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Oncogene Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


41. Randolph GW, Kamani D: [Laryngoscopy in patients undergoing thyroidectomy]. Vestn Khir Im I I Grek; 2007;166(3):29-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a group of 365 patients undergoing thyroidectomy, the group of 21 patients with invasive thyroid malignancy was compared with 344 patients with benign thyroid disease or noninvasive cancers.
  • It was shown that the method of indirect laryngoscopic examination was a simple and efficient method for detection of vocal cord paralysis and for the assessment of involvement of the surrounding tissues by the tumor.
  • For the preoperative diagnosis of invasion of the recurrent nerve area such criteria as changed voice, results of CT and MRT were shown to be insufficiently reliable.
  • [MeSH-major] Laryngoscopy / methods. Thyroid Diseases / diagnosis. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050638.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


42. Chang T, Husain AN, Colby T, Taxy JB, Welch WR, Cheung OY, Early A, Travis W, Krausz T: Pneumocytic adenomyoepithelioma: a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation. Am J Surg Pathol; 2007 Apr;31(4):562-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pneumocytic adenomyoepithelioma: a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation.
  • Pulmonary tumors with epithelial and myoepithelial differentiation are rare, thought to be of bronchial minor salivary gland origin and classified similarly to salivary gland neoplasms.
  • Some glands were filled with colloidlike secretion and had an inner, cuboidal epithelial cell layer (pankeratin, epithelial membrane antigen, and thyroid transcription factor-1 positive), surrounded by an outer layer of myoepithelial cells merging with foci of spindled myoepithelial cells (high molecular weight keratin, S100, smooth muscle actin, calponin, caldesmon, and p63 positive).
  • There were also some glands lined by a single layer of plump cells that were positive for surfactant protein-A in addition to the other epithelial cell markers.
  • The biologic behavior to date has been benign.
  • This is the first reported series of a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation that differs histologically from all previously recognized pulmonary salivary gland-type and pneumocytic tumors.
  • It is a unique benign appearing neoplasm for which the designation pneumocytic adenomyoepithelioma is suggested.
  • [MeSH-major] Lung Neoplasms / pathology. Myoepithelioma / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Microscopy, Electron, Transmission. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414103.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


43. Mai KT, Elmontaser G, Perkins DG, Thomas J, Stinson WA: Benign Hürthle cell adenoma with papillary architecture: a benign lesion mimicking oncocytic papillary carcinoma. Int J Surg Pathol; 2005 Jan;13(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign Hürthle cell adenoma with papillary architecture: a benign lesion mimicking oncocytic papillary carcinoma.
  • We studied the significance of encapsulated Hürthle cell thyroid nodules with papillary structures lacking the nuclear features of papillary thyroid carcinoma (PTC); 19 cases fulfilling these criteria were encountered The patients' ages ranged from 22 to 40 years (32+/-6), and the F:M ratio was 3:1 The tumors measured from 0.5-5 cm (2+/-1.1).
  • The diameter of the tumor cell nuclei ranged from 5.6 to 7.2 microns.
  • Many nodules had nuclei displaying a fine chromatin pattern somewhat resembling those of PTC, but these were present in <20% of the tumor cells.
  • In view of (1) the encapsulation and the uniformity of the constituent cells, (2) the negative or weak immunoreactivity for galectin-3 and HBME and negative to moderate immunoreactivity for CK19, and (3) the absence or paucity of nuclear criteria for the diagnosis of PTC and the absence of lymph node metastasis in all study cases, we believe that these lesions represent the papillary variant of oncocytic follicular adenoma (Hürthle cell adenoma).
  • [MeSH-major] Adenoma / pathology. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary, Follicular / diagnosis. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Chromatin / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735853.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromatin
  •  go-up   go-down


44. Fukushima M, Ito Y, Hirokawa M, Miya A, Kobayashi K, Akasu H, Shimizu K, Miyauchi A: Excellent prognosis of patients with nonhereditary medullary thyroid carcinoma with ultrasonographic findings of follicular tumor or benign nodule. World J Surg; 2009 May;33(5):963-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent prognosis of patients with nonhereditary medullary thyroid carcinoma with ultrasonographic findings of follicular tumor or benign nodule.
  • BACKGROUND: Medullary thyroid carcinoma (MTC) accounts for only 1.4% of all thyroid malignancies in Japan.
  • Generally, MTC shows ultrasonographic findings typical of thyroid carcinoma.
  • However, in our experience, some MTC may be diagnosed as a follicular tumor or a benign nodule on ultrasonography because ultrasonographic findings of malignancy are lacking.
  • Of these patients, 54 were diagnosed as having thyroid carcinoma (malignant, or M-type) but the remaining 23 were diagnosed as having follicular tumor or benign nodule (benign, or B-type) on ultrasonography.
  • RESULTS: Clinically apparent lateral node metastasis, extrathyroid extension, and extranodal tumor extension were observed in 37%, 17%, and 11% of M-type patients, respectively, but none of the B-type patients showed any of these features.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnostic imaging. Carcinoma, Medullary / diagnostic imaging. Thyroid Neoplasms / diagnostic imaging
  • [MeSH-minor] Adult. Aged. Calcitonin / blood. Carcinoembryonic Antigen / blood. Diagnosis, Differential. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Survival Analysis. Thyroidectomy. Ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Apr 15;77(8):1556-65 [8608543.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):415-9 [15837050.001]
  • [Cites] Eur J Endocrinol. 2007 Jul;157(1):85-93 [17609406.001]
  • [Cites] Nature. 1993 Jun 3;363(6428):458-60 [8099202.001]
  • [Cites] Clin Investig. 1993 Jan;71(1):7-12 [8095831.001]
  • [Cites] Surg Oncol. 2000 Nov;9(3):111-8 [11356339.001]
  • [Cites] Medicine (Baltimore). 1984 Nov;63(6):319-42 [6503683.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1305-11 [15517484.001]
  • [Cites] Am J Clin Pathol. 1978 Oct;70(4):587-94 [360824.001]
  • [Cites] Cancer. 1992 Aug 15;70(4):808-14 [1643612.001]
  • [Cites] Laryngoscope. 2005 Aug;115(8):1445-50 [16094121.001]
  • [Cites] Thyroid. 2007 Dec;17 (12 ):1269-76 [17988196.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):815-21 [17968174.001]
  • [Cites] Mayo Clin Proc. 1992 Oct;67(10):934-40 [1434853.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1139-48 [10699905.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):806-16 [2448025.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1367-72 [11038208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1579-83 [7906417.001]
  • [Cites] J Surg Oncol. 2005 Jul 1;91(1):56-60 [15999359.001]
  • [Cites] Thyroid. 2007 Jul;17(7):635-8 [17696833.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):880-7; discussion 887-8 [10363903.001]
  • [Cites] Diagn Cytopathol. 2000 Jun;22(6):351-8 [10820528.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):132-8 [8988737.001]
  • [Cites] World J Surg. 2006 Jan;30(1):84-90 [16369705.001]
  • [Cites] Hum Mol Genet. 1993 Jul;2(7):851-6 [8103403.001]
  • [Cites] World J Surg. 2009 Jan;33(1):58-66 [19005720.001]
  • [Cites] Thyroid. 1996 Aug;6(4):305-10 [8875751.001]
  • [Cites] Endocr J. 2004 Oct;51(5):453-6 [15516777.001]
  • [Cites] World J Surg. 1996 Sep;20(7):848-53; discussion 853 [8678961.001]
  • (PMID = 19198929.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 9007-12-9 / Calcitonin
  •  go-up   go-down


45. Lee JM, Kim JW, Song JY, Lee JK, Lee NW, Kim SH, Lee KW: Adenocarcinoma arising in mature cystic teratoma: a case report. J Gynecol Oncol; 2008 Sep;19(3):199-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign cystic teratoma is recognized as one of the most common tumors in women during the reproductive age and frequently is treated by pelviscopic operation.
  • Malignant transformation of a benign cystic teratoma is a rare event, and adenocarcinoma is extremely rare, and distinguishing this malignant change from benign disease preoperatively is nearly impossible even by the use of radiological imaging or various tumor markers.
  • We present a case with thyroid papillary carcinoma of follicular variant arising from mature cystic teratoma removed by laparoscopic salpingo-oophorectomy followed by staging laparotomy.
  • We briefly reviewed literatures with regard to malignant transformation of a benign cystic teratoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2007 Jul;15(3):318-20 [17652549.001]
  • [Cites] Pathol Res Pract. 2006;202(7):531-5 [16713128.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):140-4 [16445624.001]
  • [Cites] Obstet Gynecol Surv. 1957 Dec;12(6):793-830 [13493921.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1326-33 [9788856.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2249-55 [9610706.001]
  • [Cites] Obstet Gynecol Surv. 2000 Dec;55(12):738-45 [11128910.001]
  • [Cites] Gynecol Oncol. 1992 Jun;45(3):248-53 [1319383.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1988 Dec;29(4):329-38 [3229546.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):597-9 [15297213.001]
  • [Cites] Pathol Int. 2004 Feb;54(2):139-43 [14720146.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):338-41 [12893196.001]
  • [Cites] Arch Gynecol Obstet. 2002 Dec;267(2):107-9 [12439559.001]
  • [Cites] Arch Pathol Lab Med. 1993 Jun;117(6):647-9 [8503739.001]
  • (PMID = 19471568.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676465
  • [Keywords] NOTNLM ; Adenocarcinoma / Malignant transformation / Mature cystic teratoma / Tumor marker
  •  go-up   go-down


46. Meyer EL, Wagner MS, Maia AL: [Iodothyronine deiodinases expression in thyroid neoplasias]. Arq Bras Endocrinol Metabol; 2007 Jul;51(5):690-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Iodothyronine deiodinases expression in thyroid neoplasias].
  • [Transliterated title] Expressão das iodotironinas desiodases nas neoplasias tireoidianas.
  • The iodothyronine deiodinases constitute a family of selenoenzymes that catalyze the removal of iodine from the outer ring or inner ring of the thyroid hormones.
  • The activating enzymes, deiodinases type I (D1) and type II (D2), are highly expressed in normal thyroid gland.
  • Benign or malignant neoplastic transformation of the thyroid cells is associated with changes on the expression of these enzymes, suggesting that D1 or D2 can be markers of cellular differentiation.
  • Abnormalities on the expression of both enzymes and also of the deiodinase type III (D3), that inactivates thyroid hormones, have been found in other human neoplasias.
  • So far, the mechanism or implications of these findings on tumor pathogenesis are not well understood.
  • Nevertheless, its noteworthy that abnormal expression of D2 can cause thyrotoxicosis in patients with metastasis of follicular thyroid carcinoma and that increased D3 expression in large hemangiomas causes severe hypothyroidism.
  • [MeSH-major] Carcinoma, Papillary / enzymology. Iodide Peroxidase / metabolism. Thyroid Neoplasms / enzymology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Gene Expression Regulation, Enzymologic / physiology. Hemangioma / enzymology. Hemangioma / genetics. Humans. RNA, Messenger / genetics. RNA, Messenger / metabolism. Thyroid Gland / enzymology. Thyroxine / metabolism. Triiodothyronine / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891232.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 06LU7C9H1V / Triiodothyronine; EC 1.11.1.- / iodothyronine deiodinase type I; EC 1.11.1.- / iodothyronine deiodinase type II; EC 1.11.1.- / iodothyronine deiodinase type III; EC 1.11.1.8 / Iodide Peroxidase; Q51BO43MG4 / Thyroxine
  • [Number-of-references] 86
  •  go-up   go-down


47. Wang X, Koch S: Positron emission tomography/computed tomography potential pitfalls and artifacts. Curr Probl Diagn Radiol; 2009 Jul-Aug;38(4):156-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the recent use of 18-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) for tumor staging and treatment response, it is important to recognize many pitfalls, artifacts, and benign uptakes that are commonly encountered.
  • Normal physiology can explain many regions of increased FDG activity, as well as incidental benign tumors and benign metabolic conditions.
  • Recognition of characterization of benign causes and physiologic variants for FDG uptake are discussed to avoid improper characterization as a malignancy.
  • Also presented is the rationale for expected, benign uptake in various metabolic diseases, as well as pharmacologic methods for decreasing the artifacts caused by metabolic diseases.
  • PET/computed tomographic evaluation of the thyroid, thymus, adrenal adenomas, uterus and ovaries, infection/inflammatory changes, and postradiation/chemotherapy changes are also discussed, with expected normal changes, as well as pitfalls and artifacts.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464586.001).
  • [ISSN] 1535-6302
  • [Journal-full-title] Current problems in diagnostic radiology
  • [ISO-abbreviation] Curr Probl Diagn Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 44
  •  go-up   go-down


48. Nishihara E, Miyauchi A, Hirokawa M, Kudo T, Ohye H, Ito M, Kubota S, Fukata S, Amino N, Kuma K: Benign thyroid teratomas manifest painful cystic and solid composite nodules: three case reports and a review of the literature. Endocrine; 2006 Oct;30(2):231-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign thyroid teratomas manifest painful cystic and solid composite nodules: three case reports and a review of the literature.
  • Benign thyroid teratomas are rare in adolescents and adults.
  • We report on three cases of benign thyroid teratomas that presented as painful tumors in the neck after puberty.
  • The tumor adjacent to the thyroid in each case showed rapid enlargement with predominant cystic lesions within several months.
  • Ultrasonography and computed tomography revealed few findings suggesting the origin of the tumor.
  • Cytological examination and culture of the aspirate failed to show cells originating from the thyroid or infectious findings, but revealed a small population of columnar epithelial cells or squamous epithelial cells.
  • The patients subsequently underwent resection of the tumor, and microscopic examination revealed various types of tissue including pancreas, adipose, cartilage, muscle, and skin, and the cystic wall was lined by gastric, intestinal, respiratory, and stratified squamous epithelium.
  • Surgical resection was curative, and subsequent histologic examination revealed mature benign teratomas of the thyroid.
  • The main characteristic of our cases presented the painful tumors due to the enlarged cystic formation lined by a variety of different types of epithelium, which agreed with previous cases of benign thyroid teratomas in adolescents and adults.
  • [MeSH-major] Pain / diagnosis. Teratoma / diagnosis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1984 Oct;108(10):835-7 [6206822.001]
  • [Cites] Acta Radiol. 2004 Feb;45(1):111-2 [15164790.001]
  • [Cites] Acta Pathol Jpn. 1986 Jun;36(6):935-43 [3766140.001]
  • [Cites] Hum Pathol. 1985 Jan;16(1):56-64 [2982716.001]
  • [Cites] Surgery. 1985 May;97(5):613-7 [3992484.001]
  • [Cites] J Pediatr Surg. 1988 Jun;23(6):583-91 [3047360.001]
  • [Cites] Br J Surg. 1959 Mar;46(199):466-72 [13651623.001]
  • [Cites] Am J Otolaryngol. 2000 Mar-Apr;21(2):112-5 [10758996.001]
  • [Cites] Eur J Pediatr Surg. 2004 Apr;14(2):117-9 [15185159.001]
  • [Cites] J Formos Med Assoc. 2005 Jul;104(7):514-7 [16091830.001]
  • [Cites] Surg Today. 1997;27(5):469-72 [9130356.001]
  • [Cites] Thorax. 1975 Oct;30(5):510-5 [1198389.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1149-58 [10699906.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):700-6 [15832097.001]
  • [Cites] Surgery. 1986 Nov;100(5):932-7 [3775664.001]
  • [Cites] Am J Dis Child. 1967 Feb;113(2):222-4 [6019438.001]
  • [Cites] Ann Thorac Surg. 1991 Jan;51(1):110-2 [1985547.001]
  • [Cites] Ann Thorac Surg. 1992 Oct;54(4):741-3 [1384444.001]
  • [Cites] S Afr J Surg. 1966 Oct-Dec;4(4):181-5 [5977300.001]
  • [Cites] Teratology. 1974 Oct;10(2):111-8 [4428419.001]
  • (PMID = 17322585.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


49. Ishikawa T, Miwa M, Uchida K: Quantitation of thyroid peroxidase mRNA in peripheral blood for early detection of thyroid papillary carcinoma. Thyroid; 2006 May;16(5):435-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitation of thyroid peroxidase mRNA in peripheral blood for early detection of thyroid papillary carcinoma.
  • We applied quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) to detect tissue-specific mRNAs in circulating cancer cells for the diagnosis of early-stage cancer.
  • By Northern blotting, the thyroid peroxidase gene (TPO) was strictly expressed in the thyroid.
  • We also used RT-PCR to examine TPO and thyroid stimulating hormone receptor (TSHR) mRNAs in peripheral blood in 33 thyroid papillary carcinoma patients at stages I (23 cases), II (8 cases) and III (3 cases), 49 noncancer patients with benign thyroid diseases, and 20 healthy volunteers.
  • TPO mRNA was detected in 14 of 23 (61%) cases of stage I carcinoma but only 2 of 49 cases with benign thyroid disease.
  • By real-time quantitative RT-PCR, the estimated number of thyrocytes in the circulation ranged from 0.24 and 2700 cells per milliliter of whole blood in 7 of 9 patients at stages I and II, and thyrocyte number did not correlate with tumor size or serum thyroglobulin level.
  • Our results might suggest that detection and quantification of tissue-specific mRNAs (e.g., TPO) in peripheral blood could serve as a means to identify potential tumor markers at early stages of cancer.
  • [MeSH-major] Carcinoma, Papillary / blood. Carcinoma, Papillary / diagnosis. Iodide Peroxidase / blood. RNA, Messenger / metabolism. Thyroid Neoplasms / blood. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Blotting, Northern. Blotting, Southern. Child. Humans. Middle Aged. Neoplasm Metastasis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756464.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


50. Yasuda M, Hanagiri T, Ichiki Y, Uramoto H, Takenoyama M, Yasumoto K: Surgical treatment of patients with stenosis of the central airway due to tracheal tumours. Asian J Surg; 2010 Oct;33(4):212-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common histological finding was thyroid carcinoma (n = 3), followed by adenoid cystic carcinoma (n = 2), a metastatic thyroid tumour (n = 1), and a benign granular cell tumour (n = 1).
  • Three patients with a microscopic residual tumour required postoperative external radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Asian Surgical Association. Published by Elsevier B.V. All rights reserved.
  • (PMID = 21377110.001).
  • [ISSN] 0219-3108
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


51. Ohtsuki Y, Kimura M, Murao S, Okada Y, Teratani Y, Matsumoto M, Kurabayashi A, Iguchi M, Lee GH, Furihata M: Immunohistochemical and electron microscopy studies of a case of hyalinizing trabecular tumor of the thyroid gland, with special consideration of the hyalinizing mass associated with it. Med Mol Morphol; 2009 Sep;42(3):189-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and electron microscopy studies of a case of hyalinizing trabecular tumor of the thyroid gland, with special consideration of the hyalinizing mass associated with it.
  • Hyalinizing trabecular tumor (HTT) of the thyroid gland is rare and benign, and it neither recurs nor metastasizes.
  • In this lesion, tumor cells are arranged in trabeculae, in association with hyalinizing mass in the stroma.
  • Cytologically, tumor cells exhibiting many intranuclear cytoplasmic inclusions and nuclear grooves were found in association with light green-positive, irregular, fluffy membranous structures on touch smear.
  • Histopathologically, tumor cells exhibited many intranuclear cytoplasmic inclusions, and were positive for staining with antibodies to S100 protein, neuron-specific enolase, thyroglobulin, and vimentin.
  • The hyalinizing eosinophilic mass, which was positive for PAS reaction, and for staining by antibody to collagen type IV, gradually increased in the areas surrounding tumor cells.
  • This mass then appeared to replace the tumor cells, and exhibited a peculiar filiform pattern.
  • We demonstrated ultrastructurally that this pattern was composed of long, irregular, fine cytoplasmic processes of tumor cells and basal lamina-like substance in the hyalinizing mass.
  • The filiform pattern noted at light microscopic level consisted of long cytoplasmic processes of tumor cells and hyalinized mass at the ultrastructural level.
  • [MeSH-major] Hyalin. Thyroid Neoplasms
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Biopsy, Needle. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):622-34 [18367942.001]
  • [Cites] Adv Anat Pathol. 2002 Jan;9(1):7-11 [11756755.001]
  • [Cites] Hum Pathol. 1997 Dec;28(12):1366-72 [9416692.001]
  • [Cites] Med Mol Morphol. 2007 Sep;40(3):163-7 [17874049.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1683-4 [11117792.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):506-10 [15487446.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1269-73 [17001158.001]
  • [Cites] Mod Pathol. 1999 Nov;12(11):1057-61 [10574603.001]
  • [Cites] Med Mol Morphol. 2006 Dec;39(4):214-20 [17187185.001]
  • [Cites] Med Mol Morphol. 2007 Dec;40(4):221-5 [18085383.001]
  • [Cites] Diagn Cytopathol. 1994;10(1):25-9 [7516279.001]
  • [Cites] Am J Surg. 2007 Jun;193(6):707-12 [17512281.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):575-8 [10757406.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1622-6 [11117782.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):118-25 [9888712.001]
  • [Cites] Endocr Pathol. 2008 Spring;19(1):1-8 [17960500.001]
  • [Cites] Histopathology. 1989 Sep;15(3):211-24 [2478437.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):399-404 [12789921.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1615-21 [11117781.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):877-81 [10843292.001]
  • [Cites] Am J Clin Pathol. 1989 Feb;91(2):115-9 [2916458.001]
  • [Cites] Am J Surg Pathol. 1987 Aug;11(8):583-91 [2441614.001]
  • [Cites] Int J Surg Pathol. 2002 Apr;10(2):167-8; author reply 168-9 [12075413.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):859-67 [15223954.001]
  • [Cites] Pathol Int. 1995 May;45(5):399-401 [7647938.001]
  • (PMID = 19784748.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


52. Führer D, Schmid KW: [Benign thyroid nodule or thyroid cancer?]. Internist (Berl); 2010 May;51(5):611-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign thyroid nodule or thyroid cancer?].
  • Thyroid nodular disease is highly frequent and affects 20-23% of the adult population in Germany.
  • Differential diagnosis of thyroid nodules is directed at exclusion of thyroid autonomy and thyroid cancer.
  • Besides the patient's history and clinical examination, laboratory investigations (TSH-level, calcitonin screening), functional (scintiscan) and morphological imaging (ultrasound, in rare cases also CT without contrast media and MRI), as well as fine needle aspiration biopsy are useful tools in the differential diagnosis.
  • In the past years, major advances have been made in the understanding of the molecular pathogenesis of thyroid tumors.
  • This has led to the possibility of a molecular classification of thyroid tumors and may have prognostic as well as therapeutic impact.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / blood. Thyroid Neoplasms / blood. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pract. 2006 Jan-Feb;12(1):63-102 [16596732.001]
  • [Cites] J Clin Endocrinol Metab. 2009 May;94(5):1748-51 [19276237.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Nuklearmedizin. 2003 Oct;42(5):181-9 [14571314.001]
  • [Cites] Histopathology. 2010 Apr;56(5):632-40 [20459574.001]
  • [Cites] Endocr Rev. 2007 May;28(3):322-38 [17353294.001]
  • [Cites] Thyroid. 2003 Aug;13(8):803-10 [14558922.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2171-8 [16478817.001]
  • [Cites] Endocr Rev. 2005 Jun;26(4):504-24 [15615818.001]
  • [Cites] Dtsch Med Wochenschr. 2005 Aug 5;130(31-32):1831-6 [16052449.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1092-100 [14652809.001]
  • [Cites] Radiology. 2005 Dec;237(3):794-800 [16304103.001]
  • [Cites] Endocr Relat Cancer. 2007 Dec;14(4):957-77 [18045949.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):891-900 [17289376.001]
  • [Cites] Horm Metab Res. 2009 Jun;41(6):475-81 [19370508.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2092-8 [19318445.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):787-803 [16728537.001]
  • [Cites] Virchows Arch. 2009 Jul;455(1):21-33 [19543912.001]
  • [Cites] Pathologe. 2003 Sep;24(5):357-72 [12961024.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] Mol Endocrinol. 2002 May;16(5):903-11 [11981026.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Aug;94(8):2970-4 [19491231.001]
  • [Cites] Br J Cancer. 2010 Jan 19;102(2):376-82 [20029416.001]
  • [Cites] Horm Metab Res. 2009 Jun;41(6):482-7 [19370505.001]
  • [Cites] Acta Endocrinol (Copenh). 1988 Feb;117(2):145-53 [2837884.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17 ):1764-71 [15496625.001]
  • [Cites] Thyroid. 2004 Nov;14 (11):926-32 [15671771.001]
  • [Cites] Thyroid. 2009 Jun;19(6):565-612 [19469690.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2007 Oct;3(10):713-20 [17893690.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1390-3 [18198227.001]
  • [Cites] Nuklearmedizin. 2003 Jun;42(3):120-2 [12802476.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1600-8 [18270258.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):385-93 [16506015.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):531-8 [2408737.001]
  • [Cites] Histopathology. 2008 Apr;52(5):623-30 [18370959.001]
  • (PMID = 20405098.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


53. Tsurubuchi T, Yamamoto T, Tsukada Y, Matsuda M, Nakai K, Matsumura A: Meningioma associated with Werner syndrome--case report--. Neurol Med Chir (Tokyo); 2008 Oct;48(10):470-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten months later, the right convexity tumor was removed because follow-up MR imaging detected tumor growth.
  • The histological diagnosis was transitional meningioma.
  • Most meningiomas associated with Werner syndrome are benign, but are sometimes complicated with extracranial tumors such as sarcoma, thyroid carcinoma, and others.
  • [MeSH-major] Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology. Werner Syndrome / complications


54. Demirer AN, Kemal Y, Gursoy A, Sahin M, Tutuncu NB: Clinicopathological characteristics of thyroid cancer in patients on dialysis for end-stage renal disease. Thyroid; 2008 Jan;18(1):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of thyroid cancer in patients on dialysis for end-stage renal disease.
  • BACKGROUND: The prevalence rate of thyroid cancers in patients with renal failure is variable in different studies.
  • Our aim was to determine the prevalence and clinicopathological characteristics of thyroid cancers in the dialysis population and to evaluate the potential risk factors.
  • Then we compared the data of thyroid cancer patients on dialysis (n = 9) with the data of patients who had histopathologically verified benign thyroid disease on dialysis (n = 23) and with the histopathological data of thyroid cancer patients without ESRD.
  • RESULTS: Papillary thyroid cancer (PTC) was the only histotype that was found in 9 of 420 (2.1%) ESRD patients on dialysis.
  • Two patients had lymphatic metastasis at diagnosis.
  • Eight PTCs were classified as tumor-node-metastasis (TNM) stage I and one as stage II.
  • Among the analyzed factors, age (r = 0.374, p = 0.01) and duration of dialysis (r = 0.436, p = 0.007) showed a significant positive correlation with the occurrence of thyroid cancer.
  • CONCLUSIONS: We conclude that the prevalence of thyroid cancer in patients undergoing dialysis was not higher than that in the background population.
  • Age and duration of dialysis showed a significant positive correlation with the occurrence of thyroid cancer in patients on dialysis.
  • The effect of these characteristics on prognosis of thyroid cancer in dialysis patients is needed to be further evaluated.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Papillary, Follicular / pathology. Kidney Failure, Chronic / therapy. Renal Dialysis. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Case-Control Studies. Female. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prevalence. Prognosis. Retrospective Studies. Risk Factors


55. Pianta A, Puppin C, Franzoni A, Fabbro D, Di Loreto C, Bulotta S, Deganuto M, Paron I, Tell G, Puxeddu E, Filetti S, Russo D, Damante G: Nucleophosmin is overexpressed in thyroid tumors. Biochem Biophys Res Commun; 2010 Jul 2;397(3):499-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin is overexpressed in thyroid tumors.
  • Depending on the context, it can act as an oncogene or tumor suppressor.
  • No data are available on NPM expression in thyroid cells.
  • In this work, we analyzed both NPM mRNA and protein levels in a series of human thyroid tumor tissues and cell lines.
  • By using immunohistochemistry, NPM overexpression was detected in papillary, follicular, undifferentiated thyroid cancer, and also in follicular benign adenomas, indicating it as an early event during thyroid tumorigenesis.
  • In contrast, various levels of NPM mRNA levels as detected by quantitative RT-PCR were observed in tumor tissues, suggesting a dissociation between protein and transcript expression.
  • The same behavior was observed in the normal thyroid FRTL5 cell lines.
  • By using thyroid tumor cell lines, we demonstrated that such a post-mRNA regulation may depend on NPM binding to p-Akt, whose levels were found to be increased in the tumor cells, in parallel with reduction of PTEN.
  • In conclusion, our present data demonstrate for the first time that nucleophosmin is overexpressed in thyroid tumors, as an early event of thyroid tumorigenesis.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Cell Transformation, Neoplastic / metabolism. Nuclear Proteins / biosynthesis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Humans. Proto-Oncogene Proteins c-akt / metabolism. Thyroid Gland / metabolism. Transcription, Genetic. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20515654.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


61. Yu XM, Lo CY, Lam AK, Lang BH, Leung P, Luk JM: The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery; 2008 Dec;144(6):934-40; discussion 940-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma.
  • BACKGROUND: Vascular endothelial growth factor (VEGF) promotes tumor angioinvasion while VEGF-C is a potent lymphangiogenic factor.
  • This study aims at evaluating serum VEGF (sVEGF) and sVEGF-C levels in recurrent papillary thyroid carcinoma (PTC) patients.
  • METHODS: Serum samples were collected preoperatively from 85 patients with primary PTC, 44 with benign thyroid diseases, and 19 with recurrent PTC. sVEGF and sVEGF-C levels were measured by enzyme-linked immunosorbent assay.
  • Patients with recurrent PTC had significantly higher sVEGF (432 vs 263 pg/mL, P = .004) and sVEGF-C (6,433 vs 5,289 pg/mL, P = .006) levels than benign controls. sVEGF level was significantly elevated in patients with distant metastases compared with those of local recurrences only (580 vs 345 pg/mL, P = .037) while there was no significant difference of sVEGF-C level in both subgroup of patients. sVEGF, but not VEGF-C, showed a linear correlation with thyroglobulin levels in recurrent PTC patients.
  • [MeSH-major] Adenocarcinoma, Papillary / blood. Biomarkers, Tumor / blood. Neoplasm Recurrence, Local / blood. Thyroid Neoplasms / blood. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor C / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041000.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


62. Wang Y, Kowalski J, Tsai HL, Marik R, Prasad N, Somervell H, Lo PK, Sangenario LE, Dyrskjot L, Orntoft TF, Westra WH, Meeker AK, Eshleman JR, Umbricht CB, Zeiger MA: Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms. Thyroid; 2008 Oct;18(10):1055-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms.
  • BACKGROUND: Although fine-needle aspiration (FNA) biopsy of thyroid nodules is very sensitive in detecting thyroid malignancy, it remains ambiguous in 20-30% of cases.
  • Current biomarkers for thyroid cancer lack either the sensitivity or specificity to substantially address this clinical problem.
  • The aim of this study was to investigate the gene expression patterns of human telomerase reverse transcriptase (hTERT) alternative splice variants in benign and malignant thyroid tumors in an attempt to find a more reliable biomarker in the differential diagnosis of thyroid nodules.
  • METHODS: One hundred and thirty-three thyroid tumors from eight histopathological tumor types were collected from patients undergoing thyroid surgery at Johns Hopkins Hospital.
  • RESULTS: Malignant thyroid tumors exhibited a greater proportion of the active full-length hTERT transcript (0.57 +/- 0.15) than inactive splice variants, alpha(-) (0.13 +/- 0.02), or beta(-)/alpha(-)beta(-) deletion transcripts (0.30 +/- 0.11; p < 0.001).
  • The opposite was observed in benign tumors, which exhibited greater proportions of beta(-)/alpha(-)beta(-) deletion transcripts (0.64 +/- 0.08) than either the full-length (0.19 +/- 0.06) or alpha(-) deletion transcripts (0.17 +/- 0.02; p < 0.001).
  • Similar results were observed among a diagnostically challenging subset of 50 thyroid tumors that were suspicious for malignancy on FNA.
  • CONCLUSIONS: These differences in gene expression patterns of hTERT alternative splice variants may provide a useful adjunct to FNA diagnosis of suspicious thyroid tumors.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7647-54 [15520162.001]
  • [Cites] Acta Cytol. 2004 Nov-Dec;48(6):818-24 [15581168.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):342-57 [15648050.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):108-13 [15719377.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1B):509-14 [15816620.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4331-7 [15958614.001]
  • [Cites] Thyroid. 2005 Jun;15(6):583-7 [16029125.001]
  • [Cites] Thyroid. 2006 Aug;16(8):781-6 [16910881.001]
  • [Cites] Biomed Pharmacother. 2006 Sep;60(8):396-404 [16904860.001]
  • [Cites] Oncologist. 2007 Jan;12(1):20-37 [17227898.001]
  • [Cites] J Neurol Sci. 2007 Apr 15;255(1-2):69-76 [17350048.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1432-49 [17416541.001]
  • [Cites] Endocrinol Metab Clin North Am. 2007 Sep;36(3):707-35, vi [17673125.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Biometrics. 1988 Sep;44(3):837-45 [3203132.001]
  • [Cites] PCR Methods Appl. 1994 Jun;3(6):332-7 [7920237.001]
  • [Cites] J Am Coll Surg. 1997 Jun;184(6):605-10 [9179117.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2144-7 [9187112.001]
  • [Cites] Hum Mol Genet. 1997 Nov;6(12):2011-9 [9328464.001]
  • [Cites] Surgery. 1997 Dec;122(6):1137-40 [9426430.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2177-80 [9649130.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4168-72 [9751630.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):220-4 [9988278.001]
  • [Cites] Mol Carcinog. 1999 Dec;26(4):312-20 [10569808.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):330-5 [10652422.001]
  • [Cites] Neoplasia. 2000 Sep-Oct;2(5):426-32 [11191109.001]
  • [Cites] Ann Surg. 2001 May;233(5):716-22 [11323510.001]
  • [Cites] Mol Hum Reprod. 2001 Sep;7(9):853-7 [11517292.001]
  • [Cites] Diagn Cytopathol. 2002 Jan;26(1):41-4 [11782086.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):19-21 [11789725.001]
  • [Cites] J Pathol. 2002 Sep;198(1):37-46 [12210061.001]
  • [Cites] Cancer Lett. 2003 Mar 10;191(2):223-7 [12618337.001]
  • [Cites] Neoplasia. 2003 May-Jun;5(3):193-7 [12869302.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):584-94 [15234240.001]
  • [Cites] Cell Mol Life Sci. 2004 Jul;61(14):1764-74 [15241552.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1561-7 [10102626.001]
  • [Cites] Oncogene. 1999 Feb 4;18(5):1219-26 [10022128.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5762-8 [15355904.001]
  • [Cites] Gene. 1999 May 17;232(1):97-106 [10333526.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1483-9 [10389936.001]
  • (PMID = 18816183.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21CA81162
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC2857449
  •  go-up   go-down


63. Aqueveque A C, González E P, Gutiérrez B D, Jaimovich F R, Díaz P JC, Csendes G P, Orellana P P, Lavados M H, Alliende G I, Araya L S: [Fusion of SPECT with computed tomography or magnetic resonance for the interpretation of abnormal tracer uptake]. Rev Med Chil; 2007 Jun;135(6):725-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Utilidad clínica de la fusión SPECT/CT con marcadores externos en patología oncológica.
  • These were classified before and after the fusion as probably malignant or probably benign.
  • RESULTS: Seventy percent of patients had a differentiated thyroid carcinoma.
  • Therefore the suspicion of malignancy was presumptively confirmed in 72% of foci and fusion results would have reached a 27% of incremental diagnostic value in 14 cases that changed of category (11 with differentiated thyroid carcinoma, one with colorectal cancer, one with a nasal Ewing sarcoma and one with a brain tumor).
  • CONCLUSIONS: The fusion of SPECT and CT is useful in selected patients, specially those with differentiated thyroid carcinoma.
  • [MeSH-major] Carcinoma / diagnosis. Magnetic Resonance Imaging / methods. Radiopharmaceuticals. Thyroid Neoplasms / diagnosis. Tomography, Emission-Computed, Single-Photon / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728898.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


64. Kim DH, Murovic JA, Tiel RL, Moes G, Kline DG: A series of 146 peripheral non-neural sheath nerve tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg; 2005 Feb;102(2):256-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: This is a retrospective review of 146 surgically treated benign and malignant peripheral non-neural sheath tumors (PNNSTs).
  • Tumor classifications with patient numbers, locations of benign PNNSTs, and surgical techniques and adjunctive treatments are presented.
  • The results of a literature review regarding tumor frequencies are presented.
  • METHODS: One hundred forty-six patients with 111 benign and 35 malignant PNNSTs were treated between 1969 and 1999 at the Louisiana State University Health Sciences Center (LSUHSC).
  • The benign tumors included 33 ganglion cysts, 16 cases of localized hypertrophic neuropathy, 12 lipomas, 12 tumors of vascular origin, and 11 desmoid tumors.
  • The locations of benign PNNSTs were the following: 33 in the brachial plexus region, 39 in an upper extremity, one in the pelvic plexus, and 38 in a lower extremity.
  • There were two melanomas metastatic to nerve and one tumor each that had metastasized from the bladder, rectum, skin, head and neck, and thyroid, and from a primary Ewing sarcoma.
  • CONCLUSIONS: There were more benign PNNSTs than malignant ones.
  • Benign tumors were relatively equally distributed in the brachial plexus region and upper and lower extremities, with the exception of the pelvic plexus, which had only one tumor.
  • [MeSH-major] Brachial Plexus Neuropathies / surgery. Hypogastric Plexus / surgery. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Academic Medical Centers. Arm / innervation. Brachial Plexus / pathology. Brachial Plexus / surgery. Diagnosis, Differential. Electromyography. Follow-Up Studies. Humans. Leg / innervation. Louisiana. Magnetic Resonance Imaging. Neurologic Examination. Peripheral Nerves / pathology. Peripheral Nerves / surgery. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739553.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Zhao Z, Wei Q, Zhao Y, Sun F, Jin X, Cui B, Ning G: Genetic copy number alterations and IL-13 expression differences in papillary thyroid cancers and benign nodules. Endocrine; 2009 Aug;36(1):155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic copy number alterations and IL-13 expression differences in papillary thyroid cancers and benign nodules.
  • Thyroid nodules were the extremely common endocrine tumors, in which papillary thyroid carcinomas (PTCs) were the most prevalent endocrine malignancy, representing 80-90% of all thyroid malignancies.
  • It was still a dilemma to discriminate PTCs and benign thyroid nodules.
  • With a new molecular genetics technology of Multiplex ligation-dependent probe amplification (MLPA), we investigated 13 PTC and 14 benign nodule tissue samples.
  • The results showed that PTCs had more genetic copy number alteration than benign nodules (P < 0.001).
  • Receiver operating characteristic (ROC) curve analysis suggested that genomic aberrations would provide a moderate accuracy method to discriminate PTCs and benign nodules.
  • The gain of interleukin 13 (IL-13) gene obviously identified the great difference between PTCs and benign nodules.
  • The current study showed that MLPA should be an effective method to diagnose PTCs and benign thyroid nodules, and also provided a clue to another relationship between IL-13 and PTCs.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Papillary / genetics. Interleukin-13 / genetics. Neoplasms / genetics. Thyroid Neoplasms / genetics. Thyroid Nodule / genetics
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Gene Dosage. Genetic Testing / methods. Humans. Immunohistochemistry. Male. Middle Aged. Thyroid Gland / metabolism. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1995 Dec 21;11(12):2459-67 [8545102.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1690-4 [9135009.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1631-42 [16884377.001]
  • [Cites] Oncogene. 2008 Jul 31;27(33):4592-602 [18408749.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3735-9 [8097324.001]
  • [Cites] J Dermatol Sci. 2005 Oct;40(1):51-7 [16054806.001]
  • [Cites] J Urol. 1997 Sep;158(3 Pt 1):948-53 [9258124.001]
  • [Cites] Cancer Res. 1996 Aug 1;56(15):3583-8 [8758930.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2035-43 [15041723.001]
  • [Cites] Am J Hum Genet. 1998 Aug;63(2):625-37 [9683604.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1743-9 [9816125.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):666-9 [9024273.001]
  • [Cites] Dig Liver Dis. 2008 Apr;40(4):240-7 [18243827.001]
  • [Cites] Br J Cancer. 2000 May;82(10):1717-23 [10817509.001]
  • [Cites] Nature. 1993 Mar 18;362(6417):248-50 [8096327.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17 ):1764-71 [15496625.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Int J Colorectal Dis. 2009 Jan;24(1):57-67 [18758789.001]
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):9-16 [15714058.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):162-71 [11410861.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):17193-201 [10358077.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2414-20 [15126572.001]
  • [Cites] Blood. 1994 Sep 15;84(6):1913-21 [7521694.001]
  • [Cites] Surgery. 2000 Dec;128(6):888-93;discussion 893-4 [11114620.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1539-47 [10329606.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):296-301 [15483090.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):65-73 [17227125.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • (PMID = 19507063.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-13
  •  go-up   go-down


66. Mete O, Rotstein L, Asa SL: Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension. Ann Surg Oncol; 2010 Feb;17(2):386-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension.
  • INTRODUCTION AND DESIGN: Endocrine pathologists, surgeons, and oncologists who manage patients with thyroid carcinomas confront many critical dilemmas.
  • Controversies surrounding diagnostic criteria that distinguish benign from malignant thyroid follicular lesions have been brought to the attention of this community.
  • In this article, we confront another controversy, the definition of a thyroid "capsule" to clarify what constitutes extrathyroidal extension (ETE) and its clinical significance in the management of patients with differentiated thyroid carcinomas.
  • RESULTS AND CONCLUSION: Our review of the anatomy of the thyroid gland confirms that this structure has no defined anatomical fibrous capsule.
  • Moreover, the presence of adipose tissue within the thyroid gland and its pseudocapsule implies that thyroid tumor within fat tissue cannot be accepted as a criterion of ETE by that thyroid carcinoma.
  • While invasion of skeletal muscle is a more reliable feature of ETE, at the isthmus, these fibers can be normally present within the gland, and this criterion does not have value.
  • [MeSH-major] Connective Tissue / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Humans. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Thyroid Gland / anatomy & histology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19949881.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


67. Cheema Y, Olson S, Elson D, Chen H: What is the biology and optimal treatment for papillary microcarcinoma of the thyroid? J Surg Res; 2006 Aug;134(2):160-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the biology and optimal treatment for papillary microcarcinoma of the thyroid?
  • BACKGROUND: Papillary microcarcinomas of the thyroid, defined as tumors measuring < or =10 mm, are believed to be a less aggressive subset of papillary cancers that behave more like benign lesions and are often more conservatively treated.
  • METHODS: From May 1994 to October 2004, 184 patients underwent thyroid surgery at the University of Wisconsin and had papillary thyroid cancer present in the resected gland.
  • Of these patients, 10 were excluded because there was no record of tumor size.
  • The mean tumor size was 5.7 +/- 0.38 mm.
  • CONCLUSION: Papillary microcarcinomas of the thyroid are quite common, comprising almost half of all papillary cancers.
  • Thus, papillary microcarcinomas appear to have a similar biology to other low risk papillary thyroid cancers and, in our opinion, may warrant similar treatment.
  • [MeSH-major] Carcinoma, Papillary / surgery. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Iodine Radioisotopes / therapeutic use. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local / epidemiology. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780882.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


68. Rossi ED, Raffaelli M, Minimo C, Mule A, Lombardi CP, Vecchio FM, Fadda G: Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Cancer; 2005 Apr 25;105(2):87-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies.
  • BACKGROUND: Fine-needle aspiration biopsy (FNAB) is the most reliable diagnostic tool for thyroid nodules.
  • A difficult cytologic diagnosis may be supported by an immunocytochemical study.
  • DESIGN: Thyroid FNABs (n = 99) with both conventional (CS) and thin-layer cytology (TLC) smears were studied.
  • The cases were diagnosed as follows: 5 benign lesions (BL), 13 papillary carcinomas (PC), and 81 follicular proliferations (FP).
  • The category of FP was divided into three subgroups according to nuclear features of follicular cells: Follicular neoplasm (FN NOS), oxyphilic follicular neoplasm (OFN), and follicular lesion with nuclear pleomorphism (FLWNP).
  • Out of 37 FP, the ICCP yielded positive in 15 cases (4 benign, 11 malignant) and negative in 11 (all benign).
  • In the FLWNP subgroup, the ICCP was positive in 11 (84.6%) and negative in 2 histologically benign cases.
  • CONCLUSION: The combined panel of antibodies and the nuclear pleomorphism of follicular cells were effective in distinguishing between thyroid nodules requiring surgery from thyroid nodules requiring just follow-up.
  • [MeSH-major] Cytodiagnosis / methods. Immunohistochemistry / methods. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies. Biomarkers, Tumor / immunology. Biopsy, Fine-Needle. Carcinoma, Papillary / pathology. Female. Galectin 3 / immunology. Humans. Male. Middle Aged. Oncogene Proteins / immunology. Proto-Oncogene Proteins c-ret. Receptor Protein-Tyrosine Kinases / immunology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 American Cancer Society.
  • (PMID = 15742329.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Oncogene Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


69. Dionigi G, Dionigi R, Bartalena L, Tanda ML, Piantanida E, Castano P, Annoni M, Boni L, Rovera F, Bacuzzi A, Vanoli P, Sessa F: [Current indications for thyroidectomy]. Minerva Chir; 2007 Oct;62(5):359-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid surgery, one of the most common interventions in endocrine surgery, is practiced by many specialists who perform this procedure exclusively.
  • Surgeons who correctly perform thyroid surgery can achieve excellent outcomes even in other areas of endocrine surgery.
  • Numerous studies have reported that the incidence of complications is high and that the rate is growing: 5% involve permanent injury to the recurrent laryngeal nerve after intervention for a benign tumor, despite repeated reports that the incidence could be reduced to near zero or at least to 1%.
  • [MeSH-major] Thyroid Diseases / surgery. Thyroidectomy
  • [MeSH-minor] Algorithms. Ambulatory Surgical Procedures. Goiter, Nodular / surgery. Graves Disease / surgery. Humans. Minimally Invasive Surgical Procedures. Thyroid Neoplasms / surgery. Thyroid Nodule / surgery. Thyrotoxicosis / surgery. Treatment Outcome. Video-Assisted Surgery

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947947.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 105
  •  go-up   go-down


70. Wynveen C, Behmaram B, Haasler G, Rao N: Diverse histologic appearances in pulmonary mucinous cystic neoplasia: a case report. J Med Case Rep; 2008;2:312
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diverse histologic appearances in pulmonary mucinous cystic neoplasia: a case report.
  • INTRODUCTION: Primary pulmonary mucinous cystic neoplasia comprises a group of tumors, from benign cystadenoma to mucinous cystadenocarcinoma.
  • A lobectomy was performed and the resection specimen revealed a multicystic mucinous tumor.
  • Microscopically, the tumor was composed of confluent mucin-filled cystic spaces lined by columnar mucin-secreting cells which ranged from cytologically bland to moderately atypical with 'bronchioloalveolar pattern' invasion into the adjacent parenchyma.
  • Immunohistochemically, tumor cells were positive diffusely for Cytokeratin 7, and focally for Cytokeratin 20 and Thyroid Transcription Factor-1.
  • CONCLUSION: This case highlights the continuous spectrum of pulmonary mucinous cystic neoplasia from benign mucinous cystadenoma to malignant mucinous cystadenocarcinoma, and the probable existence of a 'borderline' mucinous cystic tumor.
  • Although molecular data are lacking to substantiate progression from benign to malignant in these neoplasms, the importance of recognizing the morphologic continuum lies in alerting pathologists to thoroughly examine specimens to rule out invasive foci in tumors with 'borderline' morphology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cardiothorac Surg. 2005 Jul;28(1):176-7 [15939602.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):62-70 [15923171.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1540-4 [8635055.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):722-8 [8317612.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):958-62 [16831050.001]
  • [Cites] Hum Pathol. 1991 Feb;22(2):185-90 [2001880.001]
  • [Cites] Mod Pathol. 1992 Nov;5(6):634-8 [1369799.001]
  • [Cites] Thorax. 1978 Dec;33(6):796-9 [746508.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):442-52 [15087663.001]
  • [Cites] Ann Thorac Surg. 2003 Nov;76(5):1738-40 [14602331.001]
  • [Cites] J Clin Pathol. 2002 Feb;55(2):156 [11865017.001]
  • [Cites] Ann Thorac Surg. 2001 Feb;71(2):696-7 [11235730.001]
  • (PMID = 18823534.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2564958
  •  go-up   go-down


71. Leinung S, Möbius C, Udelnow A, Hauss J, Würl P: Histopathological outcome of 597 isolated soft tissue tumors suspected of soft tissue sarcoma: a single-center 12-year experience. Eur J Surg Oncol; 2007 May;33(4):508-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this present report was to analyze the patients referred to us with the presumptive diagnosis of soft tissue sarcoma (STS).
  • Open biopsy revealed soft tissue sarcoma in 318 cases, benign mesenchymal tumor in 124 cases and isolated metastases (ISTM) from carcinomas in 98 patients; other pathologies were found in 57 patients.
  • The primary carcinomas were lung cancer in 26 patients, breast cancer in 19 patients, renal carcinoma in 16 patients, carcinoma of the esophagus in 12 patients, colonic carcinoma in 5 patients, thyroid gland cancer in 6 patients, and in 14 patients carcinoma of unknown primary was diagnosed.
  • CONCLUSIONS: In our collective with soft tissue tumor, 50% of the patients had the diagnosis of soft tissue sarcoma, 20% presented with a metastasis of carcinoma and 20% had a benign tumor.
  • Referring to our results, in patients with the presumptive diagnosis of soft tissue sarcomas, soft tissue metastasis of a primary carcinoma was unexpectedly common, indicating that greater consideration should be given to this differential diagnosis.
  • [MeSH-major] Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081724.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Hurtado-Lopez LM, Pacheco-Alvarez MI, Montes-Castillo Mde L, Zaldivar-Ramirez FR: Importance of the intraoperative identification of the external branch of the superior laryngeal nerve during thyroidectomy: electromyographic evaluation. Thyroid; 2005 May;15(5):449-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Comparison of 100 superior thyroid poles subjected to surgery because of benign and malignant disease, divided in three groups: G1, thyroidectomies, without searching for the EBSLN; G2, thyroidectomies, searching for the EBSLN; G3, Control, lobes, contralateral to the lobectomy, not surgically manipulated.
  • No evidence were found that injury frequency is increased by the presence of thyroid malignancy, extracapsular infiltration, or size of tumor.
  • The presence of cancer, extracapsular extension, or size of the thyroid tumor exerted no influence on the frequency of injury; localization of the nerve was the only factor affecting injury.
  • [MeSH-minor] Adolescent. Adult. Aged. Aging / physiology. Double-Blind Method. Female. Humans. Laryngeal Muscles / anatomy & histology. Laryngeal Muscles / innervation. Laryngeal Nerve Injuries. Male. Middle Aged. Sex Characteristics. Thyroid Gland / pathology. Thyroid Gland / surgery. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929666.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


73. Shantaram M, Rao A, Aroor AR, Raja A, Rao S, Monteiro F: Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors. Ann Indian Acad Neurol; 2009 Jul;12(3):162-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Glycoconjugate molecules expressed at the plasma membrane of mammalian cells have been reported to be associated with tumor progression.
  • The measurement of total sialic acid (TSA) and lipid-bound sialic acid (LBSA) in the cerebrospinal fluid (CSF) is suggested to be useful for the diagnosis of brain tumors.
  • OBJECTIVE: The objective of this study is to check the feasibility of using serum glycoconjugates such as TSA and LBSA as tumor markers in brain tumor patients.
  • The LBSA fraction was isolated from the serum of 68 brain tumor patients and evaluated using phosphotungstic acid and resorcinol; follow-up study was done on 23 patients.
  • DISCUSSION: TSA and LBSA do not have the ability to discriminate between benign and malignant brain tumors.
  • TSA and LBSA appear to be tumor markers of very limited value in patients with brain tumors.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urol Nephrol. 1992;24(2):125-9 [1624255.001]
  • [Cites] Cancer Lett. 1991 Jun 14;58(1-2):91-100 [2049789.001]
  • [Cites] J Oral Maxillofac Surg. 1991 Aug;49(8):843-7 [2072195.001]
  • [Cites] Dis Colon Rectum. 1990 Feb;33(2):139-42 [2298100.001]
  • [Cites] Adv Cancer Res. 1989;52:257-331 [2662714.001]
  • [Cites] Bull Soc Sci Med Grand Duche Luxemb. 1989 Mar-Apr;126(1):17-20 [2663215.001]
  • [Cites] Thyroid. 2005 Jul;15(7):645-52 [16053379.001]
  • [Cites] Clin Biochem. 2005 Jun;38(6):535-9 [15885233.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):912-7 [10841826.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1980 Oct;30(1):171-80 [7433766.001]
  • [Cites] Cancer. 1982 Nov 1;50(9):1815-9 [7116306.001]
  • [Cites] Clin Biochem. 1980 Oct;13(5):191-7 [7006855.001]
  • [Cites] Anticancer Res. 1984 Jul-Oct;4(4-5):313-6 [6486735.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1389-94 [3948121.001]
  • [Cites] Int J Biol Markers. 1988 Oct-Dec;3(4):243-8 [3235852.001]
  • [Cites] Clin Chim Acta. 1988 Sep 15;176(3):251-7 [3180477.001]
  • [Cites] Neurol Res. 1986 Jun;8(2):123-6 [2875407.001]
  • [Cites] Obstet Gynecol. 1988 Jan;71(1):20-6 [2827081.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1780(3):421-33 [17991443.001]
  • (PMID = 20174496.001).
  • [ISSN] 1998-3549
  • [Journal-full-title] Annals of Indian Academy of Neurology
  • [ISO-abbreviation] Ann Indian Acad Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2824932
  • [Keywords] NOTNLM ; Brain tumors / lipid-bound sialic acid / total sialic acid / tumor markers
  •  go-up   go-down


74. Nikiel B, Chekan M, Jaworska M, Jarzab M, Maksymiuk B, Lange D: [Expression of the selected adhesive molecules (cadherin E, CD44, LGAL3 and CA50) in papillary thyroid carcinoma]. Endokrynol Pol; 2006 Jul-Aug;57(4):326-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of the selected adhesive molecules (cadherin E, CD44, LGAL3 and CA50) in papillary thyroid carcinoma].
  • INTRODUCTION: The aim of the study was to determine the expression of selected adhesive molecules in papillary thyroid carcinoma.
  • MATERIAL AND METHODS: 47 papillary thyroid carcinoma cases and 11 nonmalignant goiter cases were analyzed by immunohistochemistry.
  • RESULTS: Galectin-3 (LGAL3) was a sensitive and specific marker, present in 91% of analyzed tumors and only in 5% of tumor margin.
  • CONCLUSIONS: Our study confirms the high diagnostic value of galectin-3 in papillary thyroid carcinoma and reveals the similar efficiency of CA50.
  • CD44 (DF1485) expression in primary tumor is more intensive than in surrounding tissue, but the diagnostical inportance is not high because it is often observed in benign lesions.
  • High expression of cadherin E in benign lesions impairs its diagnostical application in papillary thyroid cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology
  • [MeSH-minor] Antigens, CD44 / analysis. Antigens, Tumor-Associated, Carbohydrate / analysis. Cadherins / analysis. Diagnosis, Differential. Galectin 3 / analysis. Goiter / metabolism. Goiter / pathology. Goiter / surgery. Humans. Immunohistochemistry. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006832.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA-50 antigen; 0 / Cadherins; 0 / Galectin 3
  •  go-up   go-down


75. Besic N, Sesek M, Peric B, Zgajnar J, Hocevar M: Predictive factors of carcinoma in 327 patients with follicular neoplasm of the thyroid. Med Sci Monit; 2008 Sep;14(9):CR459-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of carcinoma in 327 patients with follicular neoplasm of the thyroid.
  • BACKGROUND: The aim of this retrospective study was to find predictive factors of carcinoma in patients with follicular neoplasm.
  • The specific aim was to discover whether preoperative serum thyroglobulin (Tg) concentration in patients with thyroid neoplasm can differentiate between those with thyroid carcinoma and those with benign disease.
  • MATERIAL/METHODS: A total of 327 patients (263 females, 64 males, median age: 51.5 years) with follicular neoplasm in whom carcinoma was only suspected and who were surgically treated at the authors' institute in 1988-2004 were included in the study.
  • RESULTS: The histopathological diagnoses were carcinoma, benign goiter, and adenoma in 119 (36%), 104 (32%), and 104 (32%) patients, respectively.
  • The independent predictors of malignancy as shown by multivariate logistic regression were tumor diameter and preoperative Tg concentration.
  • Thyroid carcinoma was more common in the patients with follicular neoplasm and serum Tg concentration over 300 ng/ml than in those with lower Tg concentrations.
  • CONCLUSIONS: Predictors of malignancy were tumor diameter and preoperative Tg concentration.
  • [MeSH-major] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / diagnosis. Thyroid Neoplasms / blood. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758416.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


76. Rodrigo JP, Rinaldo A, Devaney KO, Shaha AR, Ferlito A: Molecular diagnostic methods in the diagnosis and follow-up of well-differentiated thyroid carcinoma. Head Neck; 2006 Nov;28(11):1032-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnostic methods in the diagnosis and follow-up of well-differentiated thyroid carcinoma.
  • Thyroid cancers are the most common endocrine malignancies and are being diagnosed with increased frequency in modern clinical practice.
  • Among other diagnostic modalities, fine-needle aspiration (FNA) biopsy of clinically suspicious thyroid nodules is becoming increasingly popular.
  • Preliminary investigations have suggested that molecular diagnostic assays using tumor-specific markers may improve the sensitivity and accuracy of FNA and so may be expected to reduce the frequency of open surgical procedures by identifying those patients with demonstrably benign lesions who do not require definitive surgical excision of their lesions for diagnosis.
  • At the same time, thyroid-specific mRNA assays (especially thyroglobulin mRNA testing) have been used by investigators in the postoperative follow-up of patients with thyroid cancer as a potential means of detecting tumor recurrence in the peripheral blood.
  • Although these studies have not all reported unqualified successes--indeed, some problems based on both technical and biologic limitations have been identified-these assays still hold out the possibility that potentially important new advances in the management of patients with well-differentiated thyroid cancer may be offered by these and other molecular diagnostic methods.
  • [MeSH-major] Biomarkers, Tumor. Molecular Diagnostic Techniques. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16732600.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Fibronectins; 0 / Galectin 3; 0 / Glycoproteins; 0 / HBME-1 antigen; 0 / Membrane Proteins; 0 / oncofetal fibronectin; 124544-67-8 / HMGA1a Protein; 9010-34-8 / Thyroglobulin; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.7.49 / Telomerase
  • [Number-of-references] 80
  •  go-up   go-down


77. Bomeli SR, LeBeau SO, Ferris RL: Evaluation of a thyroid nodule. Otolaryngol Clin North Am; 2010 Apr;43(2):229-38, vii
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a thyroid nodule.
  • The thyroid specialist frequently evaluates thyroid nodules because they may represent malignancy.
  • Yet, the majority of thyroid nodules are asymptomatic and benign, so the thyroid surgeon must rely on diagnostic studies to determine when surgery is indicated.
  • Ultrasound is the preferred imaging modality for thyroid nodules, and the ultrasound guided fine-needle aspiration biopsy (FNAB) is the preferred method of tissue sampling.
  • Detecting malignancy preoperatively allows total thyroidectomy in a single operation without the need for frozen section or a second operation for completion of a thyroidectomy if malignancy is found during the initial thyroid lobectomy.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):775-9 [11448348.001]
  • [Cites] Endocr Pract. 2001 Jul-Aug;7(4):237-43 [11497473.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1941-6 [11994321.001]
  • [Cites] ANZ J Surg. 2002 Aug;72(8):570-2 [12190731.001]
  • [Cites] Am J Surg. 2002 Dec;184(6):510-4; discussion 514 [12488150.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Laryngoscope. 2003 Nov;113(11):1870-84 [14603040.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Jan;60(1):21-8 [14678283.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):163-8 [14715844.001]
  • [Cites] Radiology. 2004 May;231(2):305-32 [15044750.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5175-80 [15472223.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1764-71 [15496625.001]
  • [Cites] Thyroid. 2007 Jun;17(6):557-65 [17614777.001]
  • [Cites] Arch Intern Med. 1994 Aug 22;154(16):1838-40 [8053752.001]
  • [Cites] Immunol Today. 1995 Oct;16(10):487-94 [7576053.001]
  • [Cites] Surgery. 1995 Dec;118(6):996-1003; discussion 1003-4 [7491545.001]
  • [Cites] Otolaryngol Clin North Am. 1996 Aug;29(4):577-91 [8844731.001]
  • [Cites] Cancer. 1997 Aug 25;81(4):253-9 [9292740.001]
  • [Cites] Thyroid. 1998 Jan;8(1):15-21 [9492148.001]
  • [Cites] Thyroid. 1998 May;8(5):393-8 [9623729.001]
  • [Cites] J Clin Endocrinol Metab. 1955 Oct;15(10):1270-80 [13263417.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9 [16174717.001]
  • [Cites] Surgery. 2005 Dec;138(6):1166-74; discussion 1174-5 [16360405.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):216-22 [16434896.001]
  • [Cites] J Nucl Med. 2006 May;47(5):770-5 [16644746.001]
  • [Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]
  • [Cites] Endocr Pathol. 2006 Spring;17(1):61-5 [16760581.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3411-7 [16835280.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Nov;65(5):660-6 [17054470.001]
  • [Cites] Nucl Med Commun. 2007 May;28(5):373-81 [17414887.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Jul;139(1):21-6 [18585556.001]
  • [Cites] Endocrinol Metab Clin North Am. 2008 Jun;37(2):401-17, ix [18502334.001]
  • [Cites] Diagn Cytopathol. 2008 Jun;36(6):425-37 [18478609.001]
  • [Cites] Clin Otolaryngol. 2008 Feb;33(1):63-6 [18302559.001]
  • [Cites] Surgery. 2007 Dec;142(6):837-44; discussion 844.e1-3 [18063065.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 May;66(5):678-83 [17381488.001]
  • [Cites] Endocrinol Metab Clin North Am. 2001 Jun;30(2):339-60, viii-ix [11444166.001]
  • [Cites] World J Surg. 2000 Aug;24(8):934-41 [10865037.001]
  • [Cites] Semin Nucl Med. 2000 Apr;30(2):81-7 [10787188.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2092-8 [19318445.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 May;17(3):211-5 [19384080.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9 [18682506.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • (PMID = 20510711.001).
  • [ISSN] 1557-8259
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115902-04; United States / NCI NIH HHS / CA / R01 CA115902; United States / NCI NIH HHS / CA / R01 CA115902-04
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 44
  • [Other-IDs] NLM/ NIHMS177041; NLM/ PMC2879398
  •  go-up   go-down


78. Ersoz S, Sert H, Yandi M, Erem C, Mungan S, Ersoz HO, Cobanoglu U, Hacihasanoglu A: The significance of Galectin-3 expression in the immunocytochemical evaluation of thyroid fine needle aspiration cytology. Pathol Oncol Res; 2008 Dec;14(4):457-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of Galectin-3 expression in the immunocytochemical evaluation of thyroid fine needle aspiration cytology.
  • The aim of this study is to evaluate the significance of immunohistochemical expression of Galectin-3 in the differential diagnosis of benign and malignant thyroid nodules.
  • We studied the fine needle aspiration specimens of 38 patients who had evaluated for nodular goiter and undergone a thyroid surgery between 2004-2005.
  • None of the cases with a benign thyroid pathology had positive staining for Galectin-3.
  • Galectin-3 immunocytochemical staining, had a sensitivity of 61.5%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 83.3% for thyroid malignancies.
  • For the evaluation of follicular neoplasm, Galectin-3 immunocytochemical staining had a sensitivity of 60%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 50%.
  • Galectin-3 expression in thyrocytes is a strong indicator of a malignant proliferative lesion especially for papillary and to an extent in follicular thyroid neoplasms.
  • Galectin-3 could be used as a supplementary marker for cytological diagnosis.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Papillary / diagnosis. Biomarkers, Tumor / analysis. Galectin 3 / biosynthesis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 1993;9(3):345-50 [8519202.001]
  • [Cites] Thyroid. 1998 May;8(5):377-83 [9623727.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):449-53 [14585093.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Mayo Clin Proc. 1997 Oct;72(10):913-6 [9379692.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2637-41 [9703921.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3267-71 [7542167.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Pathol Annu. 1989;24 Pt 1:161-98 [2654836.001]
  • [Cites] Acta Cytol. 2006 Jan-Feb;50(1):28-34 [16514837.001]
  • [Cites] Oncogene. 1992 Dec;7(12):2507-11 [1461653.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3494-502 [10550147.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4530-4 [8813152.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2475-84 [10357421.001]
  • (PMID = 18415710.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


79. Papi G, Corrado S, LiVolsi VA: Primary spindle cell lesions of the thyroid gland; an overview. Am J Clin Pathol; 2006 Jun;125 Suppl:S95-123
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary spindle cell lesions of the thyroid gland; an overview.
  • Spindle cell lesions of the thyroid gland (T-SCL) are not encountered routinely in clinical practice or in the context of thyroid pathology.
  • Primary T-SCL can be derivedfromfollicular, C-cell (parafollicular), or mesenchymal components and may be the result of reactive or neoplastic processes, including post-fine-needle aspiration spindle cell nodules, Riedel thyroiditis, solitary fibrous tumor, leiomyoma, peripheral nerve sheath tumor, hyalinizing trabecular tumor, spindle epithelial tumor with thymus-like differentiation, follicular dendritic cell tumor, medullary carcinoma, papillary carcinoma, anaplastic carcinoma, sarcoma, squamous cell carcinoma, and carcinoma showing thymus-like differentiation.
  • Because T-SCL may represent the expression of benign and highly malignant neoplasms, distinction among these processes is crucial because it dictates therapy and defines prognosis.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Neoplasms, Fibrous Tissue / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16830961.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 354
  •  go-up   go-down


80. Gong Y, Jalali M, Staerkel G: Fine needle aspiration cytology of a thyroid metastasis of metaplastic breast carcinoma: a case report. Acta Cytol; 2005 May-Jun;49(3):327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of a thyroid metastasis of metaplastic breast carcinoma: a case report.
  • Because of the heterogeneous nature of this tumor, cytologic interpretation on fine needle aspirates can be quite challenging.
  • This is especially true of metastatic lesions of this rare tumor type.
  • Metastasis to the thyroid has not been previously reported.
  • CASE: A 57-year-old woman with a history of metaplastic breast carcinoma for which she underwent mastectomy, chemotherapy and radiation therapy 2 years earlier presented with a fast-growing left thyroid mass with progressive hoarseness and dysphasia.
  • Clinical presentation and findings from a neck computed tomographic scan were strongly suggestive of a primary thyroid malignancy.
  • The aspirate specimen was composed of scant, highly atypical epithelial cells in a background of an abundant chondromyxoid matrix and scattered, benign follicular cells.
  • CONCLUSION: This case emphasizes the value of clinical information and the importance of generous sampling in achieving a correct diagnosis of metastatic metaplastic carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / secondary. Thyroid Gland / pathology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966298.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Muñoz E, Prat A, Adamo B, Peralta S, Ramón y Cajal S, Valverde C: A rare case of malignant solitary fibrous tumor of the spinal cord. Spine (Phila Pa 1976); 2008 May 20;33(12):E397-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of malignant solitary fibrous tumor of the spinal cord.
  • OBJECTIVE: We present a case of an ambulatory patient with a solitary fibrous tumor of the spinal cord.
  • SUMMARY OF BACKGROUND DATA: Solitary fibrous tumor (SFT) is an uncommon mesenchymal tumor of the pleural cavity, increasingly recognized at numerous extrathoracic sites, including, among others, prostate, kidney, and thyroid.
  • Although SFTs are usually indolent neoplasms that are cured with complete surgical resection, malignant transformation has been described within histologically benign SFTs.
  • RESULTS: We report the first case of spinal cord SFT with visceral dissemination years after the primary diagnosis, despite benign histologic features of the primary tumor.
  • [MeSH-major] Liver Neoplasms / secondary. Lung Neoplasms / secondary. Solitary Fibrous Tumors / pathology. Spinal Cord Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496336.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Vimentin
  • [Number-of-references] 14
  •  go-up   go-down


82. Lin YK, Sheng JM, Zhao WH, Wang WB, Yu XF, Teng LS, Ma ZM: [Multifocal papillary thyroid carcinoma: clinical analysis of 168 cases]. Zhonghua Wai Ke Za Zhi; 2009 Mar 15;47(6):450-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multifocal papillary thyroid carcinoma: clinical analysis of 168 cases].
  • OBJECTIVE: To investigate the clinical features and treatment of multifocal papillary thyroid carcinoma (PTC).
  • One hundred and sixty-eight cases of the patients presented with multiple tumor masses (> or = 2).
  • The risk factors, including sex of the patients, age at diagnosis, family history of thyroid tumor, multiplicity and bilaterality of tumor, extra-thyroidal extension, lymph node involvement and other were analyzed between solitary PTC and multifocal PTC group.
  • Tumor foci were found in both thyroid lobes in 117 cases (69.6%).
  • Patients with multifocal PTC were characterized by a higher ratio of male (P = 0.004), family history of thyroid tumor (P = 0.031), neck lymph node metastasis (P = 0.008) and extra-thyroidal extension (P = 0.001).
  • However, solitary PTC tended to be with a higher rate of benign goiters in pathologic examination.
  • In multifocal PTC group, male, neck lymphadenectasis, > or = 3 tumor masses or bilaterality of tumor tended to presented with larger tumor, more neck lymph node metastasis and extra-thyroidal extension; And a less malignant tumor in the cases detected with benign goiters in histological examination.
  • Recurrence occurred in 8 patients and were re-resected, 2 in remnant thyroid and 6 in neck lymph nodes.
  • [MeSH-major] Carcinoma, Papillary / surgery. Thyroid Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19595234.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


83. Beil CM, Keberle M: Oral and oropharyngeal tumors. Eur J Radiol; 2008 Jun;66(3):448-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is a large variability of tumors and tumor-like lesions, which are located in the oral cavity and oropharynx.
  • About 10% of all oral and oropharyngeal tumors are benign.
  • Congenital lesions, like vascular malformations, lingual thyroid or (epi-)dermoid cyst, usually become present in youth or childhood.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Diagnostic Imaging. Mouth Neoplasms / diagnosis. Oropharyngeal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457933.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 18
  •  go-up   go-down


84. Xu J, Capezzone M, Xu X, Hershman JM: Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1beta in human papillary thyroid cancer cells. Mol Endocrinol; 2005 Feb;19(2):527-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1beta in human papillary thyroid cancer cells.
  • We previously demonstrated that the human nicotinamide N-methytransferase (NNMT) gene was highly expressed in many papillary thyroid cancers and cell lines.
  • The expression in other papillary and follicular cancers or cell lines and normal thyroid cells was low or undetectable.
  • BHP 14-9) NNMT gene expression, and expressed weakly in follicular thyroid cancer cell lines.
  • HNF-1beta was not expressed or expressed very weakly in other papillary, follicular, and Hurthle cancer cell lines and primary cultures of normal thyroid cells and benign thyroid conditions.
  • Cotransfection of a HNF-1beta expression plasmid increased NNMT promoter activity significantly in both HNF-1beta-positive and -negative thyroid cancer cell lines and Hep G2 liver cancer cells.
  • In summary, HNF-1beta functions as a transcription activator for NNMT gene expression in some papillary thyroid cancer cells.
  • [MeSH-major] Adenocarcinoma, Papillary / enzymology. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Methyltransferases / genetics. Methyltransferases / metabolism. Promoter Regions, Genetic. Thyroid Neoplasms / enzymology. Transcription Factors / metabolism
  • [MeSH-minor] Base Sequence. Binding Sites. Blotting, Western. Catalysis. Cell Line. Cell Line, Tumor. Cell Nucleus / metabolism. Cloning, Molecular. Enzyme Activation. Gene Deletion. Genes, Reporter. Hepatocyte Nuclear Factor 1-beta. Humans. Luciferases / metabolism. Molecular Sequence Data. Mutation. Nicotinamide N-Methyltransferase. Plasmids / metabolism. Protein Binding. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Gland / metabolism. Transcriptional Activation. Transfection

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15486044.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / HNF1B protein, human; 0 / Transcription Factors; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta; EC 1.13.12.- / Luciferases; EC 2.1.1.- / Methyltransferases; EC 2.1.1.1 / NNMT protein, human; EC 2.1.1.1 / Nicotinamide N-Methyltransferase
  •  go-up   go-down


85. Namasivayam S, Martin DR, Saini S: Imaging of liver metastases: MRI. Cancer Imaging; 2007;7:2-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific characterization of liver metastases in patients with primary non-hepatic tumors is crucial to avoid unnecessary diagnostic work-up for incidental benign liver lesions.
  • MR contrast agents provide critical tumor characterization and can be safely used in patients with iodine contrast allergy and renal failure.
  • The degree and nature of tumor vascularity form the basis for liver lesion characterization based on enhancement properties.
  • Neuroendocrine tumors including carcinoid and islet cell tumors, renal cell carcinoma, breast, melanoma, and thyroid carcinoma are tumors most commonly causing hypervascular hepatic metastases, which may develop early enhancement with variable degrees of washout and peripheral rim enhancement.
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1407-13 [7484575.001]
  • [Cites] Radiology. 1995 Aug;196(2):471-8 [7617863.001]
  • [Cites] Radiology. 1996 Mar;198(3):881-7 [8628887.001]
  • [Cites] Radiology. 1996 May;199(2):513-20 [8668804.001]
  • [Cites] Radiology. 1996 Jul;200(1):59-67 [8657946.001]
  • [Cites] Radiology. 1996 Sep;200(3):785-92 [8756932.001]
  • [Cites] J Magn Reson Imaging. 1996 Mar-Apr;6(2):291-4 [9132092.001]
  • [Cites] Eur Radiol. 1997;7(2):275-80 [9038130.001]
  • [Cites] Radiology. 1997 May;203(2):449-56 [9114103.001]
  • [Cites] Acta Radiol. 1997 Jul;38(4 Pt 2):626-30 [9245955.001]
  • [Cites] Acta Radiol. 1997 Jul;38(4 Pt 2):631-7 [9245956.001]
  • [Cites] Radiol Clin North Am. 1998 Mar;36(2):287-97 [9520982.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2005 May;13(2):241-54, v-vi [15935310.001]
  • [Cites] Radiol Clin North Am. 2005 Sep;43(5):861-86, viii [16098344.001]
  • [Cites] Cancer Imaging. 2005;5 Spec No A:S149-56 [16361131.001]
  • [Cites] AJR Am J Roentgenol. 2006 Apr;186(4):1051-8 [16554578.001]
  • [Cites] Radiology. 2006 Apr;239(1):122-30 [16493012.001]
  • [Cites] Eur Radiol. 2006 Jun;16(6):1337-45 [16453115.001]
  • [Cites] Cancer Imaging. 2006;6:33-42 [16766267.001]
  • [Cites] Eur Radiol. 2006 Sep;16(9):1898-905 [16691378.001]
  • [Cites] Radiology. 1999 Oct;213(1):86-91 [10540645.001]
  • [Cites] Radiology. 2000 Apr;215(1):89-94 [10751472.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2000 Nov;8(4):741-56 [11149677.001]
  • [Cites] Clin Liver Dis. 2002 Feb;6(1):73-90 [11933597.001]
  • [Cites] Clin Liver Dis. 2002 Feb;6(1):165-79, vii [11933587.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jul;151(1):79-84 [3259825.001]
  • [Cites] Radiology. 1992 Jan;182(1):167-74 [1309218.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jan-Feb;17(1):67-74 [8419443.001]
  • [Cites] Radiology. 1994 Dec;193(3):657-63 [7972804.001]
  • [Cites] Radiology. 1995 Dec;197(3):575-7 [7480718.001]
  • (PMID = 17293303.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC1804118
  •  go-up   go-down


86. Drozd VM, Lushchik ML, Polyanskaya ON, Fridman MV, Demidchik YE, Lyshchik AP, Biko J, Reiners C, Shibata Y, Saenko VA, Yamashita S: The usual ultrasonographic features of thyroid cancer are less frequent in small tumors that develop after a long latent period after the Chernobyl radiation release accident. Thyroid; 2009 Jul;19(7):725-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usual ultrasonographic features of thyroid cancer are less frequent in small tumors that develop after a long latent period after the Chernobyl radiation release accident.
  • BACKGROUND: The Chernobyl accident resulted in an unprecedented number of radiation-induced thyroid cancers in young individuals as detected by national and international screening programs.
  • The vast majority of thyroid malignancies were papillary carcinomas that, despite being similar by histopathology, displayed large variability in clinical course.
  • The correlations between ultrasound (US) and clinicopathological features in young patients with radiation-induced thyroid cancer, however, have not been well studied.
  • Because of the importance of US for deciding which subjects should have fine-needle aspiration biopsy, we assessed the US features of papillary thyroid carcinoma in patients exposed to Chernobyl fallouts.
  • DESIGN: We performed a retrospective multivariate logistic regression analysis of US features, clinicopathological data, and the latency period between radiation exposure and the diagnosis of cancer in 94 patients who were 10.6-34.3 years old (16.5 +/- 6.2, mean +/- standard deviation) at the time of diagnosis and 0.1-18.0 years old (5.6 +/- 4.2) at the time of the Chernobyl accident.
  • Irregular tumor margins correlated with the shorter period of latency (p = 0.009) and unilateral nodal disease (p = 0.010).
  • CONCLUSIONS: Irregular nodule margins, a usual sign of malignancy, are less useful in detecting thyroid cancers in radiation-exposed patients with tumors less than 10 mm.
  • Thyroid cancers that are detected after longer latent periods display less of the US features characteristic of a malignant process, while benign US features are observed more frequently.
  • Therefore, we recommend fine-needle aspiration biopsy to ensure early diagnosis of thyroid cancer for patients with a history of radiation exposure, even if their nodules are less than 10 mm.
  • [MeSH-major] Chernobyl Nuclear Accident. Neoplasms, Radiation-Induced / ultrasonography. Thyroid Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445629.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Palermo S, Di Matteo FM, Savino G, Di Marco C, Catania A, De Antoni E: [Micromedullary thyroid carcinoma: school experience]. G Chir; 2010 Jun-Jul;31(6-7):299-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Micromedullary thyroid carcinoma: school experience].
  • [Transliterated title] Il microcarcinoma midollare della tiroide: esperienza di Scuola.
  • Medullary microcarcinomas occurrence are rare and fortuitous, it's usually related to the calcitonin measurement, that's the gold standard for the diagnosis.
  • In other cases performing a thyroidectomy for a benign thyroid disease it's found a sub-centimeter tumor.
  • In this study 17 patients were operated for medullary thyroid microcarcinoma and the Authors found central lymph node metastases in 33.3% of cases.
  • [MeSH-major] Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / surgery. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646376.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 9007-12-9 / Calcitonin
  •  go-up   go-down


88. Sippel RS, Elaraj DM, Khanafshar E, Zarnegar R, Kebebew E, Duh QY, Clark OH: Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid. World J Surg; 2008 May;32(5):702-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid.
  • BACKGROUND: A fine needle aspiration (FNA) diagnosis of a Hürthle cell neoplasm is associated with a 20% risk of malignancy.
  • We sought to determine if the primary tumor size correlated with the risk of malignancy in patients with a preoperative FNA diagnosis of a Hürthle cell neoplasm.
  • METHODS: Between January 2000 and November 2006, 57 patients underwent a thyroidectomy with a preoperative FNA diagnosis of a Hürthle cell neoplasm.
  • RESULTS: The overall rate of malignancy in patients with Hürthle cell neoplasms was 21%.
  • The average tumor size was 3.2 cm, with malignant tumors being significantly larger than benign tumors (5.0 vs. 2.7 cm, p<0.01).
  • The risk of malignancy directly correlated with tumor size.
  • CONCLUSIONS: Tumor size correlates directly with malignant potential in patients with Hürthle cell neoplasms of the thyroid.
  • Because the risk of malignancy is greater than 50% in patients with a tumor larger than 4 cm, consideration should be given for an initial total thyroidectomy in these patients.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Thyroid Neoplasms / pathology. Tumor Burden

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2006 May;34(5):330-4 [16604553.001]
  • [Cites] World J Surg. 2005 Feb;29(2):164-8 [15650796.001]
  • [Cites] Surgery. 2005 Oct;138(4):650-6; discussion 656-7 [16269293.001]
  • [Cites] Endocr Regul. 2000 Mar;34(1):19-21 [10808248.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4595-601 [12364440.001]
  • [Cites] Cytopathology. 2001 Dec;12(6):399-405 [11843942.001]
  • [Cites] Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Dec;14(4):541-57 [11289734.001]
  • [Cites] Am J Surg. 2006 May;191(5):593-7 [16647343.001]
  • [Cites] Cancer. 2006 Apr 25;108(2):102-9 [16453320.001]
  • [Cites] Am Surg. 2002 Oct;68(10):907-10 [12412723.001]
  • [Cites] Eur J Surg Oncol. 2004 Sep;30(7):786-9 [15296995.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):253-8 [10472925.001]
  • [Cites] Surgery. 2004 Dec;136(6):1160-8 [15657571.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Eur J Surg Oncol. 2006 May;32(4):458-61 [16497473.001]
  • [Cites] Cancer. 2000 Jul 1;89(1):202-17 [10897019.001]
  • [Cites] Ann Surg. 1998 Apr;227(4):542-6 [9563543.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1186-94 [12599224.001]
  • [Cites] Diagn Cytopathol. 2004 Nov;31(5):307-12 [15468114.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):179-84 [8423216.001]
  • [Cites] World J Surg. 2001 Sep;25(9):1160-3 [11571953.001]
  • [Cites] World J Surg. 2004 Aug;28(8):761-5 [15457355.001]
  • [Cites] Arch Surg. 1983 May;118(5):529-32 [6838358.001]
  • [Cites] Cytopathology. 2006 Oct;17(5):245-50 [16961652.001]
  • [Cites] Surgery. 1999 Oct;126(4):798-802; discussion 802-4 [10520931.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jan;132(1):54-8 [16415430.001]
  • [Cites] Horm Res. 1997;47(4-6):145-57 [9167946.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1266-70 [15517492.001]
  • (PMID = 18224463.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Lyshchik A, Higashi T, Asato R, Tanaka S, Ito J, Mai JJ, Pellot-Barakat C, Insana MF, Brill AB, Saga T, Hiraoka M, Togashi K: Thyroid gland tumor diagnosis at US elastography. Radiology; 2005 Oct;237(1):202-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid gland tumor diagnosis at US elastography.
  • PURPOSE: To prospectively evaluate the elastographic appearance of thyroid gland tumors and explore the potential sensitivity and specificity of ultrasonographic (US) elastography for differentiating benign and malignant tumors, with histopathologic analysis as the reference standard.
  • Fifty-two thyroid gland lesions (22 malignant, 30 benign) in 31 consecutive patients (six men, 25 women; mean age, 49.7 years +/- 14.7 [standard deviation]) were examined with real-time elastography in the elasticity imaging mode implemented on a clinical US scanner modified for research.
  • In addition, normal thyroid gland tissue and thyroid gland tumor strains were measured on off-line processed elastograms, and the thyroid gland-to-tumor strain ratio (ie, strain index) was calculated.
  • The potential of elastographic criteria for the diagnosis of thyroid gland cancer was evaluated with univariate analysis and multivariate logistic regression.
  • RESULTS: A strain index value greater than 4 on off-line processed elastograms was the strongest independent predictor of thyroid gland malignancy (P < .001); this criterion had 96% specificity and 82% sensitivity.
  • Two other elastographic criteria, which were evaluated on real-time elastograms--a margin regularity score higher than 3 (88% specificity, 36% sensitivity) and a tumor area ratio higher than 1 (92% specificity, 46% sensitivity)--also were associated with malignancy (P < .05).
  • CONCLUSION: Elastography is a promising imaging technique that can assist in the differential diagnosis of thyroid cancer.
  • [MeSH-major] Thyroid Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Biomechanical Phenomena. Cysts / ultrasonography. Diagnosis, Differential. Elasticity. Female. Humans. Logistic Models. Male. Middle Aged. Sensitivity and Specificity. Thyroid Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2005
  • (PMID = 16118150.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


90. Ferreira RC, Ward LS, Adam RL, Leite NJ, Metze K, Matos PS: [Contribution of nuclear texture analysis for the differential diagnosis of follicular lesions of the thyroid: comparison to immunohistochemical markers]. Arq Bras Endocrinol Metabol; 2009 Oct;53(7):804-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Contribution of nuclear texture analysis for the differential diagnosis of follicular lesions of the thyroid: comparison to immunohistochemical markers].
  • [Transliterated title] Contribuição da análise de textura do núcleo celular para o diagnóstico diferencial de lesões foliculares da tireoide: comparação com marcadores imunoistoquímicos.
  • OBJECTIVE AND METHODS: To investigate the utility of nuclear chromatin texture assessment in the differential diagnosis of follicular patterned lesions, by means of examining 76 samples previously submitted to the immunohistochemical protein analysis of HBME-1, CK-19 and galectina-3.
  • Among these variables, r(2), a parameter related to the granularity of the nucleus presented the best accuracy, sensitivity, specificity and positive and negative predictive values, distinguishing benign from malignant lesions.
  • CONCLUSION: The morphometric analysis of nuclear chromatin images may add accuracy to the differential diagnosis of follicular patterned lesions.
  • [MeSH-major] Adenoma / pathology. Biomarkers, Tumor / analysis. Carcinoma, Papillary, Follicular / pathology. Cell Nucleus / pathology. Chromatin / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Computer-Assisted / methods. Diagnosis, Differential. Galectin 3 / analysis. Humans. Keratin-19 / analysis. Predictive Value of Tests. Software

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arq Bras Endocrinol Metabol. 2009 Oct;53(7):793-4 [19942979.001]
  • (PMID = 19942981.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromatin; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19
  •  go-up   go-down


91. Kim E, Bae TS, Kwon Y, Kim TH, Chung KW, Kim SW, Ro J, Lee ES: Primary malignant teratoma with a primitive neuroectodermal tumor component in thyroid gland: a case report. J Korean Med Sci; 2007 Jun;22(3):568-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant teratoma with a primitive neuroectodermal tumor component in thyroid gland: a case report.
  • Most teratomas involving the thyroid are benign and occur in children.
  • However, the adult cases reported are mostly malignant and commonly arise in the thyroid.
  • The patient underwent extensive evaluation of the thyroid gland with computed tomography (CT) scan and positron emission tomography (PET) scan, which revealed no evidence of metastatic disease.
  • This is the first case, to our knowledge, of malignant thyroid teratoma with a exuberant primitive neuroectodermal tumor component in Korea.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / complications. Neuroectodermal Tumors, Primitive / pathology. Teratoma / complications. Teratoma / pathology. Thyroid Gland / pathology
  • [MeSH-minor] Adult. Female. Head and Neck Neoplasms / pathology. Humans. Neoplasm Metastasis. Positron-Emission Tomography / methods. Thyroid Diseases / diagnosis. Thyroidectomy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Mar 1;88(5):1149-58 [10699906.001]
  • [Cites] Am J Otolaryngol. 2000 Mar-Apr;21(2):112-5 [10758996.001]
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):375-9 [10833994.001]
  • [Cites] Ann Diagn Pathol. 2001 Oct;5(5):285-92 [11598856.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Thyroid. 2003 Apr;13(4):401-4 [12804109.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1015-22 [9818077.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2796-804 [7595741.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):896-904 [9255252.001]
  • [Cites] Am J Clin Oncol. 1998 Apr;21(2):212-4 [9537215.001]
  • [Cites] Ann Hematol. 1998 May;76(5):183-8 [9671130.001]
  • [Cites] Head Neck. 1998 Oct;20(7):649-53 [9744468.001]
  • [Cites] Bull Cancer. 1995;82 Suppl 1:56s-60s [7542945.001]
  • (PMID = 17596674.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2693658
  •  go-up   go-down


92. Bockhorn M, Sheu SY, Frilling A, Molmenti E, Schmid KW, Broelsch CE: Paraganglioma-like medullary thyroid carcinoma: a rare entity. Thyroid; 2005 Dec;15(12):1363-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraganglioma-like medullary thyroid carcinoma: a rare entity.
  • OBJECTIVE: The wide variety of rare histologic variants of medullary thyroid carcinoma (MTC) may make the differential diagnosis difficult.
  • Pathologic examination of the resected specimen will not always be able to confirm the diagnosis, leaving the surgeon with an uncertainty as to what type of resection is best for the patient.
  • The following report describes the case of a 58-year-old man with the rare diagnosis of paraganglioma-like MTC.
  • A 1-cm tumor was detected in the right lobe of the thyroid.
  • Based on the clinical diagnosis of MTC, we performed a total thyroidectomy with lymphadenectomy of the central and right lateral compartments.
  • Paraffin sections of the resected specimen were stained with hematoxylin and eosin (H&E) and immunohistochemically characterized using antibodies to CT, CEA, chromogranin A, thyroglobulin, synaptophysin, sustentacular cells (SCs), low- and high-molecular cytokeratins (CK 5/6, 7, 18, 20), epidermal growth factor-receptor (EGFR), thyroid transcription factor-1 (TTF-1), bcl-2, Melan A, C-kit, neuron-specific enolase (NSE), and galectin-3.
  • The patient's blood and tumor tissue were examined for mutations in the RET-protooncogene.
  • RESULTS: H&E staining of both frozen and permanent sections was unable to differentiate benign from malignant tissue.
  • Only the additional finding of positivity for synaptophysin and numerous SC cells visible in-between neoplastic cells made the diagnosis of paraganglioma-like MTC possible.
  • CONCLUSIONS: There are subgroups of MTC that present clinically similar to classic MTC, but in which missing typical morphologic characteristics make histopathology diagnosis difficult.
  • In these cases, diagnosis, operative decisions, and follow-up strategies should be based on preoperative biochemical markers, imaging findings, and clinical parameters in accordance to the guidelines for classic MTC.
  • [MeSH-major] Carcinoma, Medullary / pathology. Paraganglioma / pathology. Thyroid Neoplasms / pathology


93. Słonina J, Nienartowicz E, Agrawal AK, Malczewska J, Moroń K: [The usefulness of contrast-enhanced sonography in the differential diagnostic of adrenal tumors]. Endokrynol Pol; 2006 May-Jun;57(3):230-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The occurrence of gland tumors causes significant clinical problem.
  • The application of contrast-enhanced sonography could improve the vessels visualization and point out characteristic features of benign and malignant changes.
  • The authors believe that this new method make possible the differential adrenal tumor diagnostic process more precise and increase the specificity of ultrasonography in the recognition of benign and malignant tumors.
  • MATERIAL AND METHODS: Ultrasound examinations were made with the use of digital devise by GE Voluson 740, probe 4-6 mHz with Doppler options and volumetric probe 3D according to the following protocol: 26 patients with recognized adrenal tumor were qualified for the examination.
  • Patients in the first stage of tumor vascularization had Doppler examination with color (CD) and power Doppler (PD).
  • RESULTS: 26 cases of adrenal gland tumours were subjected to analysis.
  • 2. The use of Levovist in Doppler examination improves the visualization of tumor vascularization.
  • However, it is impossible to differentiate benign from malignant tumors unequivocally.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnostic imaging. Contrast Media. Imaging, Three-Dimensional. Polysaccharides
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neovascularization, Pathologic / diagnostic imaging. Sensitivity and Specificity. Thyroid Diseases / diagnostic imaging. Ultrasonography, Doppler, Color

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16832787.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Polysaccharides; 127279-08-7 / SHU 508
  •  go-up   go-down


94. Hussein HA, Mebeed AH, Saber TKh, Farhat IG: Hyperparathyroidism with bone tumor-like presentation, approach for diagnosis and surgical intervention. J Egypt Natl Canc Inst; 2009 Mar;21(1):1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperparathyroidism with bone tumor-like presentation, approach for diagnosis and surgical intervention.
  • AIM OF WORK: This work aims to find out a clinical approach for diagnosis of cases with hyperparathyroidism presented with bone tumor like condition as first and main presentation in order to differentiate primary bone tumors or secondary bone metastases from different types of hyperparathyroidism and to clear out the indications and type of surgery in such cases.
  • During this period we followed 45 cases of hyperparathyroidism (HPT) presented with a main complaint of bone tumor-like lesion.
  • RESULTS: Preoperative diagnosis was: 80% cases of primary hyperparathyroidism (pHPT), 15.5% cases of secondary hyperparathyroidism (sHPT), 4.5% tertiary hyperparathyroidism (tHPT), benign adenoma in 73.3%, diffuse hyperplasia in 8.8% and one case of parathyroid carcinoma.
  • Intraoperative ultrasound was useful in detection of 2 additional cases in the thyroid lobe tissue.
  • CONCLUSION: Hyperparathyroidism should be suspected in all cases with bone tumor-like presentation or even in earlier disease complain of bony or muscle aches.
  • Intact P.T.H and calcium (total &ionic), renal functions, 24 hours urine calcium, neck ultrasonography, and Tc 99m pertechnitate/Tc99m sestsmibi subtraction scan can establish the diagnosis.
  • KEY WORDS: Hyperparathyroidism - Bone tumor-like presentation - Diagnosis - Surgical approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601966.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


95. Avcu S, Ozen O, Bulut MD, Bora A: Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings. N Am J Med Sci; 2009 Nov;1(6):305-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings.
  • CONTEXT: Carcinoid tumors represent a group of well-differentiated tumors originating from the diffuse endocrine system outside the pancreas and thyroid.
  • Various sites of origin of this neoplasm are appendix - 30-45%, small bowel - 25-35% (duodenum 2%, jejunum 7%, ileum 91%, multiple sites 15-35%), rectum 10-15%, caecum - 5%, and stomach - 0.5%.
  • CASE REPORT: Here we report a case of primary jejunal carcinoid tumor in a 66-year-old woman metastasizing to liver with ultrasonography, computed tomography, and diffusion-weighted magnetic resonance imaging (DWI) findings.
  • CONCLUSION: Primary jejunal carcinoid tumor is a rare entity.
  • DWI can help in the differential diagnosis of hepatic hypervascular metastatic mass lesions from benign ones, as well as in the diagnosis of carcinoid tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22666712.001).
  • [ISSN] 2250-1541
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3364631
  • [Keywords] NOTNLM ; Carcinoid / diffusion weighted MRI / jejunum / metastases / small bowel
  •  go-up   go-down


96. Schmidt J, Derr V, Heinrich MC, Crum CP, Fletcher JA, Corless CL, Nosé V: BRAF in papillary thyroid carcinoma of ovary (struma ovarii). Am J Surg Pathol; 2007 Sep;31(9):1337-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF in papillary thyroid carcinoma of ovary (struma ovarii).
  • BACKGROUND: Malignant struma ovarii (MSO) are rare tumors that arise from ectopic thyroid tissue in the ovary, benign struma ovarii (BSO).
  • Most MSO are histologically classified as papillary thyroid carcinomas (PTC).
  • Oncogenic activation of BRAF (35% to 69%), RAS (10%), or RET (5% to 30%) is common in PTC, and the mutations correlate with tumor subtype, patient age, and clinical behavior.
  • Corresponding benign tissues were evaluated when available.
  • [MeSH-major] Carcinoma, Papillary / genetics. Gene Expression Regulation, Neoplastic. Mutation. Ovarian Neoplasms / genetics. Proto-Oncogene Proteins B-raf / genetics. Struma Ovarii / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721188.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


97. Coli A, Bigotti G, Parente P, Federico F, Castri F, Massi G: Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma. J Exp Clin Cancer Res; 2007 Jun;26(2):221-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma.
  • Ninety-six thyroid lesions were immunohistochemically evaluated for HBME-1 and Galectin-3 expression including nodules with cytological atypia, the latter defined as nuclear features suggestive but not diagnostic of papillary thyroid carcinoma.
  • Thirty nodules with cytological atypia, 49 papillary thyroid carcinomas (PTCs), 4 follicular carcinomas and 13 oxyphilic tumors were examined.
  • Forty-one of the 49 PTCs, 16 atypical thyroid nodules and 3 non-malignant oxyphilic tumors exhibited a combined expression of HBME-1 and Galectin-3.
  • In 6 of the sixteen atypical thyroid nodules the immunoreactivity for both markers was strong and diffuse, simulating the pattern observed in PTC.
  • We conclude that thyroid nodules with cytological atypia and strong/diffuse positivity for both HBME-1 and Galectin-3, two well recognized markers of PTC, represent a starting phenotypic change towards PTC, for which a benign or borderline counterpart has not yet been defined.
  • The expression of HBME-1 and Galectin-3 in some thyroid nodules is related to the presence of cytological atypia suggestive but not diagnostic of PTC.
  • The phenotypic similarity between this subset of thyroid nodules with cytological atypia and PTC is also confirmed by our data according to which Galectin-3 and HBME-1 have been found to be highly sensitive for PTC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Papillary / diagnosis. Galectin 3 / analysis. Thyroid Nodule / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725102.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen
  •  go-up   go-down


98. Yoo SC, Chang KH, Lyu MO, Chang SJ, Ryu HS, Kim HS: Clinical characteristics of struma ovarii. J Gynecol Oncol; 2008 Jun;19(2):135-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although one patient had an abnormal thyroid function test, the laboratory findings normalized after operative treatment.
  • Diagnosis by preoperative imaging studies were 8 dermoid cysts, while only 3 cases were diagnosed as struma ovarii.
  • CONCLUSION: Struma ovarii is a rare tumor.
  • The diagnosis was confirmed by pathologic findings.
  • The treatment of benign struma ovarii is surgical resection only.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2006 Mar-Apr;16(2):698-707 [16681750.001]
  • [Cites] Ceylon Med J. 2004 Sep;49(3):90-1 [15524228.001]
  • [Cites] Am J Obstet Gynecol. 1961 Apr;81:752-62 [13766579.001]
  • [Cites] Int J Gynaecol Obstet. 1993 Aug;42(2):143-6 [7901063.001]
  • [Cites] J Nucl Med. 1988 Feb;29(2):263-5 [2831319.001]
  • [Cites] Cancer. 1987 Jul 15;60(2):178-82 [3297279.001]
  • [Cites] Br J Radiol. 1990 May;63(749):360-3 [2379061.001]
  • [Cites] J Reprod Med. 1983 Jun;28(6):415-9 [6887150.001]
  • [Cites] Cancer. 1983 Jan 15;51(2):337-43 [6821820.001]
  • [Cites] Ann Intern Med. 1970 Jun;72(6):883-93 [5448747.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):543-8 [12798728.001]
  • [Cites] J Ultrasound Med. 2000 Dec;19(12):857-61 [11127011.001]
  • [Cites] Postgrad Med J. 1999 Oct;75(888):617-8 [10621907.001]
  • (PMID = 19471561.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676458
  • [Keywords] NOTNLM ; Dermoid tumor / Malignancy / Struma ovarii
  •  go-up   go-down


99. Song M, Chen FJ, Fan W, Wei MW, Chen WK: [Roles of single photo emission computed tomography-CT in detecting residual tumor from patients with thyroid carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Mar;42(3):211-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Roles of single photo emission computed tomography-CT in detecting residual tumor from patients with thyroid carcinoma].
  • OBJECTIVE: As newly, functional, diagnostic measure-18F-deoxyglucose single photo emission computed tomography (18F-FDG SPECT-CT) has well sensitivity and specialty , it was proved availability in differentiating benign and malignant tumor.
  • In this study, it was compared the efficiency of detecting residual tumor of thyroid cancer between 18F-FDG SPECT-CT and CT-TWIN.
  • METHODS: During May 2004 to August 2004, 56 patients with thyroid disease were divided into two groups, one group was 32 cases suffered thyroid tumor, another was 24 cases suffered improper operation.
  • RESULTS: Forty eight cases had been performed operation, and 8 cases waited and watched because they didn't be found residual tumor by 18F-FDG SPECT-CT and CT-TWIN.
  • The results in detecting thyroid tumor showed that the same rate of diagnostic correction of SPECT-CT was 87.5% (28/32), and the Youden index of SPECT-CT was 0.667, higher than that of CT which was 87.5% (28/32) and 0.633 respectively.
  • The rate of diagnostic correction of SPECT-CT in detecting residual tumor was 84.6%, and its Youden index was 0.675.
  • The rate of diagnostic correction of CT in detecting residual tumor was 75.0%, and its Youden index was 0.492; and the result had statistics signification by being compared two different measures.
  • CONCLUSIONS: SPECT-CT and CT all had higher diagnostic efficacy, and they could promote the diagnostic efficacy when they have the same diagnosis in detecting thyroid tumor.
  • The rate of detecting residual tumor of SPECT-CT was 81.3%, compared with that of CT the diagnostic efficacy has greater raise.
  • [MeSH-major] Neoplasm, Residual / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging. Tomography, Emission-Computed, Single-Photon

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633282.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


100. Bishop JA, Sharma R, Illei PB: Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol; 2010 Jan;41(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
  • Immunohistochemistry for thyroid transcription factor-1 is widely used in the diagnosis of pulmonary adenocarcinomas because it marks approximately 75% of lung adenocarcinomas and is negative in most squamous cell carcinomas and adenocarcinomas of other organs.
  • We performed immunohistochemistry for napsin A and thyroid transcription factor-1 using tissue microarrays of 95 adenocarcinomas, 48 squamous cell carcinomas, 6 neuroendocrine tumors of the lung, as well as 5 colonic, 31 pancreatic, and 17 breast adenocarcinomas, 38 malignant mesotheliomas, 118 renal cell carcinomas, and 81 thyroid tumors.
  • The tissue microarrays also included 15 different benign tissues.
  • Pulmonary adenocarcinomas were napsin A positive in 79 (83%) of 95 cases compared with 69 (73%) of 95 cases that were thyroid transcription factor-1 positive.
  • There were 13 napsin A-positive/thyroid transcription factor-1-negative and 2 thyroid transcription factor-1-positive/napsin A-negative tumors, increasing the number of cases that were positive with at least one of the markers to 81 (85%) of 95.
  • In the thyroid, only 2 cases of papillary thyroid carcinoma (5%), both with tall cell morphology, were positive for napsin A, whereas all other papillary and follicular carcinomas were negative.
  • As expected, all renal tumors were thyroid transcription factor-1 negative, and all thyroid tumors, except for one papillary carcinoma, were thyroid transcription factor-1 positive.
  • Napsin A is a sensitive marker for pulmonary adenocarcinoma and is also expressed in a subset of renal cell carcinomas, particularly of the papillary type, as well as in rare cases of papillary thyroid carcinomas.
  • The combined use of napsin A and thyroid transcription factor-1 results in improved sensitivity and specificity for identifying pulmonary adenocarcinoma in primary lung tumors and in a metastatic setting.
  • [MeSH-major] Aspartic Acid Endopeptidases / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Nuclear Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Colonic Neoplasms / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / metabolism. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Pancreatic Neoplasms / metabolism. Thyroid Neoplasms / metabolism. Tissue Array Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2012 Jul;43(7):1153-4; author reply 1154 [22703591.001]
  • (PMID = 19740516.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down






Advertisement